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ABSTRACT 
The field of epigenetic research in hematology and oncology is rapidly expanding. 
Even so, reliable data linking epigenetic changes to clinical outcomes are scarce. We 
conducted two retrospective studies in AML. The first (paper I) was performed in 107 
AML patients without a previous history of MDS where we approximated the global 
DNA 5-methylcytosine content with a methylation sensitive restriction enzyme assay, 
the promoter DNA methylation status of three known tumor suppressor genes, 
CDKN2B (p15), HIC1 and CDH1, and in a subset of 20 patients genome-wide 
promoter methylation by the Illumina HumanMethylation27 array. Promoter 
methylation of CDKN2B was common (66%), and associated with better overall and 
disease free survival in uni- and multivariate analysis. Average genome wide promoter 
methylation levels were also associated with overall and disease free survival and 
correlated inversely with global 5-methylcytosine content, which in turn associated 
with response to induction therapy. The second study (paper II) was restricted to 
cytogenetically normal de-novo AML cases. In a test group of 58 samples we 
investigated genome wide promoter methylation by the Illumina HumanMethylation27 
array and correlated the methylation patterns with the mutational status of NPM1, 
FLT3, CEBPA, IDH1, IDH2, DNMT3A and clinical parameters. We found increased 
promoter methylation in NPM1 and IDH mutated samples with specific methylation 
patterns for these two mutations. Compared with a control group of normal myeloid 
progenitor cells from 9 donors the most differentially methylated genes in AML were 
those that in previous studies were targeted by Polycomb group proteins in embryonic 
tissue. Furthermore, we found that the methylation levels of the Polycomb targeted 
genes were associated with overall and progression free survival. The prognostic 
association was confirmed in a validation cohort of 60 patients and retained 
significance in multivariate analysis. The third study of this thesis (paper III) was 
designed to search for the second tumor suppressor gene commonly thought to reside 
on chromosome 11q21-23 in CLL, based on the finding of two microdeletions in a 
previous study. Through DNA methylation screening we found a 48% prevalence of 
aberrant promoter methylation of the shared two-directional promoter of BTG4 / 
microRNA-34b/c. Functional studies with stress incubation of primary CLL samples as 
well as the HG3 cell line showed an selective up-regulation of miR-34b/c transcripts in 
unmethylated cells, but no induction of BTG4 regardless of methylation status. 
Chromatin immunoprecipitation experiments showed the presence of repressive 
chromatin marks in both CLL and normal lymphocytes, which may explain our 
observation that the basal expression levels of miR-34b/c were low both in normal 
lymphocytes and CLL cells regardless of methylation status, compatible with a 
“epigenetic switch” from conditional to permanent silencing in methylated samples.  
 
We conclude that DNA methylation patterns are associated with mutational status and 
clinical outcomes in AML. Furthermore we believe that miR-34b/c may function as a 
tumor suppressor gene in CLL, incapacitated by an epigenetic switch mechanism in 
approximately 50% of CLL samples. 
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1 INTRODUCTION 
1.1 EPIGENETICS-A BRIEF HISTORY 
1.1.1 The early theories 
The early history of what we today call epigenetic research is inseparable from the 
history of developmental processes and genetics. Conrad Hal Waddington (1905-1975), 
professor of Genetics at the University of Edingburgh, was the person who coined the 
term “epigenetics”, a synthesis of “epigenesis”, i.e the process of organism 
development, and “genetics”, in an effort to connect these two separate fields of 
research. He used the term with this denotation for the first time in two publications in 
1941 and 1942 [1, 2]. Several researchers contemporary with Waddington, such as 
Julian Huxley, J.B.S Haldane and Ernst Hadorn, explored the relationship between 
development and genetics, but they all had different opinions of the definition and used 
the term “epigenetics” differently[3]. Waddington also introduced the concepts of the 
“epigenetic landscape” and “canalization”, a model of explaining differentiation and 
cellular development that still is topical[4]. He developed these concepts based on the 
observations that there is an innate “robustness” of phenotypes; that nature was able to 
buffer the majority of induced genetic variations and environmental exposures, which 
would have little or no effect on the final phenotype. This concept was called 
“canalization”, elegantly illustrated in figure 1. The shape of the surface, the epigenetic 
 
Figure 1 The epigenetic landscape as described by C.H Waddington. The contour of the epigenetic 
landscape on the upper panel decides which canal the ball will follow. The network strings and 
poles in the lower panel defines the shape of the landscape in itself. Figures reprinted from the 
original publication with permission from Taylor and Francis. 
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ball at the top of the landscape ready to roll down is 
equivalent to a totipotent cell ready to travel down the 
path of di!erentiation.
Predictions from the concepts of canalization and epigenetic 
landscape
Waddington’s idea of canalization predicts that cryp-
tic genetic variations will accumulate but will not be 
expressed, because the capacity to canalize develop-
ment in a predictive manner requires these genetic vari-
ations to remain dormant and not produce phenotypic 
variations during development. Waddington suggested 
that the disruption of canalizing mechanisms, that is, a 
decanalizing event would release such hidden genetic 
variations, which would then produce phenotypic 
variations. In terms of the rolling ball on the epigenetic 
landscape metaphor, changes that a!ect the valley or 
the canal of the landscape will have a massive impact on 
the trajectory and subsequent canalization of the rolling 
ball.
Experimental evidence that provides support to the 
predictions from the concepts of canalization and epigenetic 
landscape
Waddington’s prediction that a decanalizing event is 
needed to release the phenotypic e!ects of hidden genetic 
variations seems to have been experimentally validated. 
It has been demonstrated in both Drosophila (Rutherford 
and Lindquist, 1998) and Arabidopsis (Queitsch et al., 
2002) that the impairment in heat shock protein 90 
(Hsp90) function during development results in the 
expression of phenotypic variations that can a!ect nearly 
any adult structure. "eir #ndings have demonstrated 
that widespread variations that can a!ect developmen-
tal pathways exist in the genome, but are usually silent. 
Such silencing of the e!ects of variations is mediated 
by Hsp90. When Hsp90 function is compromised, these 
cryptic genetic variations are expressed producing new 
phenotypes. Subsequent restoration of Hsp90 function 
does not revert the expression of these cryptic variations 
and the phenotypes.
Rolling ball position = totipotent cell
(can take any path in front of it)
Possible paths the
ball can follow
A
B
Ball canalized
= commited cell
(cannot reverse course)
String pulls (interactions)
determining the
landscape contour
Pegs (genes)
Figure 1. (A) Epigenetic landscape as envisioned by Waddington. !e undulating surface leading to many lower-elevation endpoints, each 
endpoint corresponds to a speci"c developmental endpoint, such as, development of a speci"c tissue. If a ball rolls down the landscape, 
its ultimate fate will be to take a s eci"c path and reach the corresponding lowest point. !us, once a cell fate is committed to achieve a 
developmental endpoint, it cannot be reversed to achieve a di#erent developmental endpoint. When the ball is at the highest point of 
elevation it can take any path in front of it (analogous to a totipotent cell). Once the ball is canalized, its fate cannot be reversed (analogous 
to committed cell). (B) Genetic interactions in determining the shape of the epigenetic landscape as proposed by Waddington. In the 
depiction, Waddington envisioned a sheet of fabric (the landscape) connected by strings (interactions) to the pegs (genes). !e pegs 
themselves are also linked to each other by strings, which represent the interactions among genes making up the landscape. !is depiction 
suggests that the pegs (genes), through their string-pulls (interactions) among themselves as well as with the fabric, confer a speci"c 
stable contour to the fabric. In other words, genetic interactions can exert their individual and collective e#ects determining the speci"c 
developmental system (Figures reprinted from Waddington’s !e Strategy of Genes 1957, Figure 4 on page 29 and Figure 5 on page 36, 
George Allen and Unwin, with permission from Taylor and Francis. Figure 1A has been modi"ed).
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landscape, is determined by elevations and valleys forming paths, or canals, in the 
landscape. If an imaginary ball would be placed on the highest point of the landscape, it 
would follow the most sloping canal down to the lowest point it could reach, which 
would be the final phenotype in a developmental system. The model can just as well be 
applied to cell differentiation, for instance hematopoiesis, where the starting point at 
“high ground” would equal the hematopoietic stem cell which subsequently 
differentiates through progenitor and increasingly differentiated stages to reach its final 
phenotype. Under the surface of the epigenetic landscape it is connected by multiple 
strings (epigenetic interactions) to firmly attached poles (genes), shaping the landscape 
above. Changing or removing individual genes (poles) or interactions (strings) would 
surely affect the shape of the landscape, but since the canals are formed by many poles 
and strings, there is an inherent robustness in the system.  
These early concepts of epigenetics did not provide any insights of specific 
mechanisms, they were rather describing a phenomenon necessary to explain 
developmental observations – bridging the gap between stable genotype and variable 
phenotype. 
 
1.1.2 The discovery of epigenetic mechanisms 
The existence of 5-methylcytosine in DNA was reported in 1948 [5] by Hotchkiss and 
confirmed by Wyatt two years later[6]. It took several decades until this discovery was 
associated with decreased gene transcription, which was first reported in 1975 
independently by three groups[7-9]. Riggs suggested a model of X-chromosome 
inactivation by DNA methylation and Holliday and Pugh that specific gene DNA 
methylation could explain the switching on and off of genes during development. Also, 
the existence of maintenance DNA methyl transferases that were sequence specific in 
themselves or bound to sequence specific proteins, were predicted. This was later 
confirmed in 1983 by the characterisation of DNA methyl transferase 1 (DNMT1) – the 
DNA methyl transferase responsible for maintenance methylation[10] and the de novo 
methyl transferases DNMT 3a and 3b in 1998[11]. The discovery and exploration of 
covalent histone modifications began long before its transcriptional consequences were 
known, mainly in the context of protein biochemistry. The earliest modifications, 
discovered in the 1960:s were histone acetylation and methylation[12]. More work on 
acetylation and its association with transcription was performed in the seventies[13], 
but the breakthrough and general acceptance of the link between histone tail acetylation 
and that this preceded and allowed for transcription to occur was not until the late 
1980:s and beginning of the 1990:s[14-17]. 
 
1.2 SPECIFIC EPIGENETIC MECHANISMS 
1.2.1 Cytosine methylation 
DNA methylation is a covalent modification of the cytosine ring at the 5´position 
typically occurring at a CpG dinucleotide. Recently, methylation of the 3´position has 
been described, but the consequences of 3-cytosine methylation are less explored [18]. 
In this thesis the term “DNA methylation” refers to 5-cytosine methylation if not 
otherwise indicated. The DNA methyltransferases are present at the replication fork 
during S-phase and DNA methylation is thus a replication dependent event[19]. CpG 
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dinucleotides are scattered across the genome but less common than would be expected 
by chance, a phenomenon attributed to the spontaneous deamination of cytosine to 
thymidine in CpG residues which has occurred during evolution[20]. Preferably in the 
promoter region of genes however, the CpG residues cluster together and form so 
called “CpG islands”, of typically 800-1200 base pairs length. They can be found in 
approximately half of all protein coding genes and in contrast to scattered CpG 
residues, the CpG dinucleotides in CpG islands are typically unmethylated[21]. The 
promoter regions are sites of transcriptional regulation and transcriptional silencing of 
DNA through DNA methylation is thought to be achieved by two direct mechanisms; 
recruitment of transcriptional repressors and interfering with DNA binding of 
transcriptional activators. Specific methyl CpG binding proteins, the MeCP;s, complex 
closely with DNA at multiple (MeCP1) or sparsely (MeCP2) methylated CpG sites 
regardless of DNA sequence[22, 23]. MeCP2 interacts with a co-repressor complex of 
proteins, including histone deacetylaces (HDACs) and histone methyltransferases 
(HMTs), reinforcing repressive chromatin state through cross talk between the DNA 
methylation system and the histone modification system[24]. Recently, focus has been 
drawn on the mechanism of 5-methylcytosine to 5-hydroxymethylcytosine conversion 
by the TET enzymes described more detailed in section 1.3.3.7. The occurrence of 5-
cytosine hydroxymethylation is thought to be very common but the exact function of 
this modified base is still under investigation. It is thought to be involved in DNA 
demethylation or gene expression regulation, however, the lack of a technique that can 
accurately and sensitively detect 5-hydroxymethylcytosine has hindered researchers to 
further explore its potential biological function. This results from the fact that 5-
hydroxymethylcytosine behaves very similar to its precursor 5-methylcytosine during 
bisulfite conversion and restriction enzyme digestion which for are used in most 
investigations of the subject, including in this thesis[25, 26]. 
 
1.2.2 Histone modifications 
The nuclear chromatin is a complex of DNA and histones organized as repetitive 
elements of so called “nucleosomes”. A nucleosome is composed of the histone 
octamer and the DNA that wraps around it in a left handed supercoil, 150 bp per 
nucleosome (Figure 2). The histone octamer consists of two molecules each of H2A, 
H2B, H3 and H4. Histone H1 links the adjacent histones together along with the “linker 
DNA”. The N-termini of the core histones protrudes from the nucleosome and is called 
the “tail”. Most, but not all, covalent histone modifications occur in the tail, all 
facilitated by specific enzymes or protein complexes.  
  12 
  
Figure 2 Organisation of chromatin, from methaphase chromosomes (bottom) 
to nucleosomes (top). Reprinted with permission from Elsevier. Choudhuri et 
al. Toxicol Appl Pharmacol. 2010 Jun 15;245(3):378-93. 
 
There are different kinds of histone modifications; acetylation, methylation, 
phosphorylation, ubiquitination, sumoylation, ADP-ribosylation. The effect they have 
on transcription is not always clear cut since it sometimes is context dependent. Histone 
methylation can for instance have both activating and repressing effects depending on 
at which amino acid the methyl group is deployed, but also depending on how many 
methyl residues are attached to that particular amino acid. For instance mono or tri-
metylation of Lysine 27 at histone 3 (H3K27), the former associated with active and the 
latter with silent chromatin. A simplified scheme is shown in table 1. 
These complex, interacting histone modifications are referred to as the “histone code”, 
a term that was invented by Strahl and Allis[27, 28] to describe the phenomenon. The 
term has gained widespread acceptance and is to be understood analogous to the digits 
on a code-lock; only a specific combination of digits will open the lock. In analogy, 
only specific histone modification combinations will open the chromatin for 
transcription. 
 
1.2.3 Micro RNA (miRNA)  
Following initial observations in plants of transcriptional inhibition 
by antisense RNA[29-31]. Craig C. Mello and Andrew Fire's 1998 Nature paper 
reported a potent gene silencing effect after injecting double stranded RNA into C. 
elegans. They were the first to recognize the mechanism behind, awarding them the 
Nobel prize in 2006[32]. They demonstrated the existence of a mechanism where 
double-stranded RNA successfully silenced the targeted gene and named the 
phenomenon RNA interference. The endogenous counterpart, micro-RNA:s were 
initially described in C. elegans in 1993[33], initially thought to be an idiosyncrasy, but 
subsequent work could show it was a highly conserved feature in multiple species[34, 
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35]. The majority of miRNA genes are intergenic or oriented antisense to neighboring 
genes and are transcribed independently[36-38]. 
 
Activating modifications Repressing 
modifications 
Acetylation  
H2A: K5, K9, K13  
H2B: K5, K12, K15, K20  
H3: K9, K14, K18, K23, K56  
H4: K5, K8, K13, K16  
Methylation Methylation 
H3: K4, K36, K79 H3: K9, K27 
H3: R17, R23 H4: K20 
H4: R3  
Phosphorylation  
H3: T3  
H3: S10, S28  
H3: Y41  
H2AX: S139 (for DNA 
repair) 
 
Ubiquitination Ubiquitination 
H2B: K120, H2A: K119 
H2B: K123 (yeast)  
 Sumoylation 
 H2A: K126 (yeast) 
 H2B: K6, K7 (yeast) 
 H4: K5, K8, K12, K16, K20 
Table 1 Some histone modification with their effect on 
transcription. Reprinted with permission form Elsevier from 
Choudhuri et al. Toxicol Appl Pharmacol. 2010 Jun 
15;245(3):378-93. 
 
They are encoded by single pri-miRNA sequences, containing from one to six miRNA 
precursors. Transcribed by DNA polymerase II these hairpin loop structures are 
composed of about 70 nucleotides each. The biogenesis is schematically illustrated in 
figure 3. The double-stranded RNA structure of the hairpins in a pri-miRNA is 
recognized by a nuclear protein  “microprocessor” complex; Drosha-DGCR8, which 
processes the pri-miRNA to pre-MIRs[39]. Pre-MIRs have a two-nucleotide overhang 
at its 3’ end and have 3' hydroxyl and 5' phosphate groups. These are exported to the 
cytoplasm and further processed by Dicer, an RNAse II enzyme, resulting in an 
imperfect miRNA:miRNA duplex of about 22 nucleotides in length[40, 41]. The 
mature miRNAs are incorporated into an active RNA-induced silencing complex 
(RISC) containing Dicer, Argonaut2 and many associated proteins[42]. 
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Using the miRNA as a guide, the RISC complex induces specific genetic silencing, 
either via mRNA degradation or by preventing mRNA from being translated. It has 
been demonstrated that if there is complete complementation between the miRNA and 
target mRNA sequence, Arogonaut2 can cleave the mRNA and lead to direct mRNA 
degradation. Yet, if there isn't complete complementation the silencing is achieved by 
preventing translation[42-44]. In humans about 1000 miRNAs have been 
described[45], and there is amounting evidence of miRNA dysregulation in cancer[46-
48]. 
 
 
1.2.4 Long non coding RNA:s (ncRNAs) 
In contrast to micro RNA:s there is an abundance of non coding RNA transcripts longer 
than 200 nucleotides, on the basis of a convenient practical cut-off in RNA purification 
protocols that excludes small RNA A recent study found only one fifth of the 
transcription across the human genome is associated with protein-coding genes [49], 
indicating at least four-times more long non-coding than coding RNA sequences. 
Large-scale sequencing projects such as FANTOM (Functional Annotation of 
 
Figure 3 The biogenesis and processing steps of 
micro-RNA:s, highlighting the processing of primary 
miR:s by Drosha to pre-miR:s, nuclear export and 
Dicer processing, loading to the RISC-complex 
which, using the miR as a targeting device finds the 
implicated mRNA ORF, resulting in translation 
inhibition and/or mRNA degradation. 
RNAPolII=RNA polymerase II. DGCR8=Di George 
Syndrome Critical Region 8 gene. TRBP= 
transactivating response RNA-binding protein. 
RISC= RNA-induced silencing complex. ORF=Open 
reading frame. UTR=Untranslated region. 
Reprinted with permission from Elsevier. 
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Mammalian cDNA) further reveal the complexity of this transcription[50]. The 
FANTOM3 project identified approximately 35000 non-coding transcripts from 10000 
distinct loci that bear many signatures of mRNAs, including 5’capping, splicing and 
poly-adenylation, but have little or no open reading frames (ORF). They are typically 
transcribed by DNA polymerase III. Many of these are thought to be functional, 
however, until now only a relatively small proportion has been demonstrated to be 
biologically relevant[51, 52]. NcRNAs can target different aspects the of RNA 
transcription machinery, functioning as co-regulators, modifying transcription factor 
activity, or regulating the association and activity of other co-regulators or even 
targeting RNA polymerase II[53-55]. An example is formation of RNA-double helix 
DNA association, resulting in triple helix formation which has been shown to block the 
binding site for transtcriptional co-activator TFIID in the promoter of the dihydrofolate 
reductase gene[56]. Intriguingly, tens of thousands of similar triple helix structures 
exists throughout the genome[57]. Another type of ncRNAs are the short interspersed 
nuclear Alu-repeats, which are extremely abundant in the vertebrate genome, 
comprising approximately 10% of all DNA[58, 59]. These elements can be transcribed 
as ncRNAs as a response to stress, for instance heat shock, and bind to RNA 
polymerase II, inhibiting the formation of the pre-initiation complex[60-62]. Non 
coding RNAs also interfere with other epigenetic regulation. An example is HOTAIR, 
a ncRNA encoded from the HOXC locus which when expressed represses part of the 
HOXD locus by directing the Polycomb Repression Complex II to this locus, inducing 
histone trimethylation[63, 64]. Another example is the function of ncRNA XIST, which 
during embryonic stem cell differentiation is expressed from the X-chromosome that 
will be inactivated. It coats the X-chromosome and induces repressive chromatin 
modifications; H3K27me3, H3K9 hypermethylation and H4K20 monomethylation, 
H2AK119 monoubiquitylation and H4 hypoacetylation, resultion in inactivation[65, 
66]. In cancer the world of ncRNAs is still largely unexplored, but some studies have 
been performed. For instance, a recent study observed an inverse expression profile of 
the p15 gene and an antisense ncRNA (CDKN2BAS) in AML, correlating the degree 
of p15 DNA methylation with the level of antisense ncRNA expression[67]. 
 
1.3 ACUTE MYELOID LEUKEMIA 
1.3.1 Overview, definition and pathogenesis 
Acute Myeloid Leukemia (AML) is the predominant type of acute leukemia in adults. 
It is a disease characterized by clonal expansion of immature hematopoetic cells of the 
myeloid lineage, myeloblasts, of more than 20% in the bone marrow[68], however, the 
presence of certain chromosomal rearrangements are diagnostic with lower blast 
counts. The disease affects approximately 4/100 000 persons yearly in the western 
world which amounts to 3-400 cases yearly in Sweden[69, 70]. The median age at 
diagnosis is 71 years[71]. The classical symtoms are those of bone marrow failure, i.e. 
infections due to leukopenia, fatigue and breathlessness due to anemia and 
bleeding/bruising due to thrombocytopenia. The etiology is unknown, although 
preceding malignancies such as myelodysplastic syndromes (MDS) or 
myeloproliferative disease (MPD) are not uncommon. There is also an association with 
exposure to ionizing radiation and benzene as well as previous chemotherapy [72, 73]. 
The classification of AML has traditionally been based on morphologic features ever 
since the first French-American-British (FAB) classification of 1976[74, 75]. In an 
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effort to incorporate the growing body pathophysiological and genetic knowledge, the 
first WHO classification came in 2001 and was revised in 2008[68, 76, 77]. The WHO 
classifications took account of cytogenetic findings, relation to previous chemotherapy 
as well as the presence of dysplastic lesions. Cases that were not defined by these 
criteria fell under the “AML, not otherwise specified” group, which essentially consists 
of the old FAB classes (table 2). 
 
 
Table 2 The WHO classification of Acute Myeloid 
Leukemias 2008 
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1.3.1.1 Genetics 
Genetically, AML is one of the most studied types of neoplasms and among the first 
where genetic information was incorporated into clinical decision making[78]. 
Recurrent non random translocations, inversions and deletions are typically seen in all 
hematological malignancies including AML, for instance t(8;21), inv(16) and 
t(15;17)[79]. Furthermore, molecular aberrations such as nucleophosmin 1 (NPM1) 
mutations, fms-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD), 
CCAT/enhancer-binding protein alpha (CEBPA) and Mixed Lineage Leukemia (MLL) 
translocations have in recent years contributed to prognostic stratification[80] and also, 
in the case of FLT3-ITD, efforts of using targeted therapy[81].  
1.3.1.2 Class I and II mutations 
Given the recurrent chromosomal aberrations and molecular mutations it was suggested 
that AML is the consequence of two complementary classes of mutations: class I that 
confer a proliferative advantage by activating signal transduction pathways in 
hematopoetic/myeloid progenitors, and class II that impair differentiation and/or confer 
properties of self-renewal by affecting transcription factors or transcriptional 
activation[82, 83]. Mutations of either class are often reciprocal, but this is not 
universally found[84]. The recently discovered common mutations in AML, DNMT3A 
and IDH1 and IDH2, TET2 as well as splicing machinery (i.e SF3B1) mutations have 
not yet found their established place as class I or class II mutations[85-90], figure 4. 
Interestingly, DNMT3A, IDH and TET2 mutations all impact epigenetic aberrations or 
mechanisms. Also, which class the mutations affecting the p53 apoptotic pathway 
belongs to is also debatable, and some authors even place it in a separate class[84, 91]. 
 
Figure 4 A graphic view of class I and class II mutations. Black lines indicate concurrent 
mutations in samples, the with of the line indicates frequency among 144 patients. Red lines 
indicate concurrent mutations of the same class. Reprinted with permission from Wiley. 
European Journal of Haematology Volume 83, Issue 2, pages 90-98, 21 mar 2009 
 
 
1.3.2 Prognostic factors 
AML is a heterogeneous disease and despite advances in therapy and supportive care 
prognosis remains poor. Even for patients younger than 65 there is a clear-cut effect of 
age on survival (figure 5), with median survival at five years of 40%. Among patients 
older than 65, a dismal 20% are alive at five years after diagnosis[71, 92]. Age is an 
independent prognostic factor although the inability to cope with intensive regimens, 
adverse cytogenetics and poor performance status all increase in prevalence with 
age[93-97]. Even so, some elderly patients seem to benefit from intensive 
induction[71]. 
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Figure 5 Survival of different age cohorts in patients up to 64 years of age. Data from the Swedish 
AML registry 2010, showing a continuous decrease in survival with a possible threshold at 55 
years. Reprinted with permission. 
 
 
Table 3 Cytogenetic and molecular risk groups. Adopted from European Leukemia Net 
2010[98]. 
* Includes all AMLs with normal karyotype except for those included in the favorable 
subgroup; most of these cases are associated with poor prognosis, but they should be 
reported separately because of the potential different response to treatment. 
† For most abnormalities, adequate numbers have not been studied to draw firm conclusions 
regarding their prognostic significance. 
‡ Three or more chromosome abnormalities in the absence of one of the WHO designated 
recurring translocations or inversions, that is, t(15;17), t(8;21), inv(16) or t(16;16), t(9;11), 
t(v;11)(v;q23), t(6;9), inv(3) or t(3;3); indicate how many complex karyotype cases have 
involvement of chromosome arms 5q, 7q, and 17p. 
 
 
The karyotype of the leukemic cells is the strongest prognostic factor for response to 
induction therapy and for survival[99, 100]. Patients are routinely divided into 
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c.  
 Cumulative Proportion Surviving (Kaplan-Meier)
Include condition: Dx='APL'
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Ålder vid diagnos har mycket stor betydelse för överlevnad vid akut leukemi, även efter 
korrektion av förväntad överlevnad för åldersmatchade personer utan leukemi (visas inte i 
denna rapport). Det tycks finnas olika brytpunkter vid de olika diagnoserna, 30 år för ALL 
och AML, men även 55 år vid AML som kan sammanhänga med bedömningen av 
transplantationsindikation (se figur 8:5), och 60 år vid APL. 
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favorable, intermediate and adverse risk groups based on cytogenetic findings[79, 101-
103], see table 3. The complex karyotype has been defined differently over the years, 
with ≥5 or ≥3 cytogenetic aberrations. The current definition according to the European 
Leukemia Net is three or more chromosomal aberrations, excluding the WHO 
designated translocations or inversions. They are thought of as separate entities, since 
long recognized for the core binding leukemias; t(8;21), inv(16) as well as for APL 
t(15;17), but now also including several other (table 4)[75].  
 
Complex karyotype AML is often associated with deletion 17p and/or mutations of 
TP53[102, 103]. A recently highlighted entity is the “monosomal karyotype”, defined 
as either two autosomal monosomies or a monosomy together with at least one 
additional autosomal aberration, the presence of which infers an even worse outcome 
than the traditional complex karyotype does[104]. Especially within the group of 
patients with cytogenetically normal AML, molecular gene mutations of NPM1, FLT3 
and CEBPA have been incorporated in the prognostic stratification [78]. 
 
1.3.3 Molecular mutations in AML 
1.3.3.1 FLT3 
FMS-like tyrosine kinase 3 (FLT3) is a member of the class III receptor tyrosine kinase 
family. It is important in hematopoetic stem cell proliferation, survival and 
differentiation. Mutations are activating and of two types, affecting either the 
juxtamembrane domain or the tyrosine kinase domain. The principal juxtamembrane 
mutation is the FLT3 internal tandem repeat (FLT3-ITD) and the principal tyrosine 
kinase domain mutation is an activating point mutation (FLT3-TKD)[104-106]. 
Recently a novel type of FLT3-ITD was discovered, affecting the kinase domain in 
approximately 30% of FLT3-ITD cases[107]. FLT3-ITD occurs in approximately 20% 
of all AML cases, somewhat more in cytogenetically normal AML (CN-AML) (28-
34%). FLT3-TKD mutations are found in 5-10% of all AML but is more prevalent in 
inv(16) AML (14-24%)[80]. The clinical prognosis of AML cases with FLT3-ITD is 
significantly inferior within the CN-AML subgroup and there may be an effect of 
mutation burden on prognosis[108, 109]. 
1.3.3.2 NPM1 
Nucleophosmin 1 is a chaperone protein shuttling between the nucleus and cytoplasm. 
It has multiple functions, among them stabilisation of p14Arf in the nucleolus, ribosome 
biogenesis and export[110-113]. NPM1 mutations are typically heterozygous and 
mainly affect exon 12 resulting in disruption of the nuclear export signal and 
accumulation in the cytoplasm[114, 115]. It occurs in one third of all AML cases and 
around 60% of CN-AML and is frequently associated with FLT3-ITD and IDH 
mutations[80]. NPM1 mutated AML is a provisional entity in the 2008 WHO revised 
criteria[77, 116]. NPM1 mutations in the absence of FLT3-ITD has a favourable 
prognosis, with increased remission rates and better survival among younger 
patients[80, 115, 117], and a generally better prognosis in elderly[118]. The European 
Leukemia Net recently suggested this entity to be considered as part of the favourable 
genetic risk category together with core-binding leukemias[98]. 
1.3.3.3 CEBPA 
CCAAT enhancer binding protein alpha (CEBPA) is a transcription factor involved in 
myeloid differentiation. Mutations of CEBPA occur in 7% of all AML cases but more 
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often in CN-AML (10-18%). Mutations affect the N-terminal (nonsense mutation) 
and/or C-terminal (in frame mutations), both giving rise to dysfunctional proteins[119]. 
In one third of CEBPA mutated cases one allele, and in two thirds both alleles are 
mutated; 90% having an N-terminal mutation on one and C-terminal on the other allele, 
called compound heterozygotes[120, 121]. These double mutant cases are associated 
with a higher CR rate and favourable survival[122-124]. Even transcriptional silencing 
of CEBPA, notably often by methylation of its distal promoter, has been shown to be of 
prognostic significance[125, 126]. 
1.3.3.4 IDH1 and IDH2 
Isocitrate dehydrogenase (IDH) 1 and 2 are metabolic enzymes that are rate limiting in 
the Krebs cycle and are hence strictly regulated. Its physiological function is to convert 
isocitrate to α-ketoglutarate, but the mutated forms instead cause a gain of function, 
facilitating production of 2-hydroxyglutatate. The mutations are always heterozygous 
and IDH1 and IDH2 mutations are more or less mutually exclusive[127, 128]. Both 
forms are found in approximately 16% of all AML cases, and are somewhat more 
common in CN-AML (20-37%). They have an unfavourable impact on outcome in the 
large subgroup of CN-AML with NPM1 mutations lacking FLT3-ITD [129-131]. 
Interestingly, IDH mutations and TET2 mutations are mutually exclusive and display 
similar DNA hypermethylation patterns, possibly due to the inhibitory effect of 2-
hydroxyglutarate on TET2 function[132]. 
1.3.3.5 WT1 
WT1 is a transcription factor implicated in the regulation of apoptosis, proliferation and 
differentiation of hematopoetic progenitors[133, 134]. Inactivating mutations occur in 
10-13% of CN-AML and have been associated with inferior prognosis[135, 136], but 
also without prognostic impact[137]. 
1.3.3.6 MLL 
Mixed Lineage Leukemia (MLL) is a DNA binding protein regulating gene expression 
by its histone methyltransferase activity. The MLL-partial tandem duplication (PTD) 
mutation is found in approximately 10% of CN-AML and 90% of AML with trisomy 
11[138]. MLL-PTD cases are associated with a poor prognosis and a specific DNA 
methylation profile with up-regulation of homeobox (HOX) genes[139, 140]. 
1.3.3.7 TET2 
The TET2 enzyme belongs to a family of three enzymes. The close relative TET1 
converts 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), and TET2 
mutant cases displayed decreased 5hmC-levels. DNA methylation was on the whole 
not very different, but samples from patients with low 5hmC showed hypomethylation 
relative to controls at the majority of differentially methylated CpG sites[141]. 
TET2 mutations occur in approximately 13% of all AML cases, preferably in the 
intermediate cytogenetic risk group and are more common in isolated trisomy 8 
cases[142]. Another group reported a prevalence of 23% in CN-AML cases[143]. Both 
these studies reported a negative impact on prognosis and were mutually exlusive of 
IDH mutations. 
1.3.3.8 DNMT3A 
DNMT3A is one of the de novo DNA methyl transferases. It is mutated in 
approximately 18-23% of AML cases, and is an independent poor prognostic factor for 
survival[88, 144]. It occurs more frequently in CN-AML cases with IDH, NPM1 and 
FLT3 mutations. Interestingly, global average DNA methylation levels did not differ 
from mutated vs. wild type DNMT3A cases, but had different methylation patterns. A 
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recent study shows that the ability of DNMT3A to form tetramers is impaired by 
mutations which negatively affects the binding to DNA but not the DNA methylation 
functions, compatible with disrupted methylation patterns[145]. 
 
1.3.4 Epigenetic mechanisms in AML 
1.3.4.1 Aberrant DNA methylation 
Due to the relative ease of investigating DNA methylation with standard laboratory 
techniques and the obtainability of AML blasts of relatively high purity there is a huge 
number of publications on the subject [146, 147]. In contrast with molecular and 
karyotypical aberrations, there seems to be hundreds of genes aberrantly methylated in 
AML. Depending on methodology and the number of genes investigated it seems that 
there are no cases of AML where aberrant DNA methylation is not a feature [148]. In 
line with this, there is evidence that the levels of DNMT1, DNMT3A and DNMT3B 
are increased in blast cells of AML patients [149]. Global hypomethylation were 
among the first described changes in AML [150]. The reason for the apparent 
contradiction between global hypomethylation and increased gene specific CpG island 
methylation is an issue that is not resolved. It has been suggested that alternate 
transcripts of DNMT3B, lacking the catalytic domain may be responsible [151] but 
other studies counter that [152]. Other explanations may be increased activity of DNA 
demethylases [153], folate deficiency or the previously predominant view that the 
global hypomethylation is a passive process. The crosstalk between histone 
modifications and DNA methylation is also implicated. Loss of monoacetylation of 
H4Lys16 and trimethylation of H4Lys20 in leukemia cells correlate with DNA 
hypomethylation of Sat2, NBL2 and D4Z4 tandem repeat sequences [154]. A recent 
publication where whole genome bisulfite sequencing was performed in colon cancer 
and normal controls may help to resolve this issue[155]. Hansen et al describes 
“blocks” of hypomethylated DNA covering more than half the colon cancer genome 
that largely overlap with “nuclear lamina-associated domains”, i.e. chromosomal 
regions that associate with the nuclear membrane and are transcriptionally silent[156]. 
The also describe numerous small (<5kbp) differentially methylated regions (DMR:s) 
between normal and cancer where the physiological homeostasis of hypomethylation in 
CpG islands with a loss of or shift of boundary preferably leads to hypermethylation of 
CpG islands and relative hypomethylation of CpG island shores. A minority of small 
DMR:s have the opposite characteristics, i.e hypomethylation of CpG islands and 
hypermethylation of shores. 
There is no consensus regarding the connection between global DNA hypomethylation 
and the alleged pro-neoplastic events coupled with this such as increased chromosome 
breakage, increased microsatellite instability (MSI) and concurrent defects in the 
mismatch repair system seen for instance in colon cancer [157]. MSI is however not an 
uncommon finding in AML. The prevalence of MSI ranges from 20-30% and perhaps 
even higher in therapy related and secondary AML [158]. The hMLH1 and hMSH2 
genes are involved in the DNA mismatch repair (MMR) pathway and are closely 
associated with MSI. They are silenced by promoter hypermethylation in several 
neoplasms, but this is a rare event in AML, seen in only 2-4% of cases[159]. 
Numerous studies have investigated specific gene promoters for methylation in AML 
and the number of individual genes found hypermethylated is exhaustive[160-168]. An 
interesting finding is the inverse correlation of age and the number of genes methylated 
found in one study, perhaps indicative of a different methylation pattern in de novo 
AML [169]. On a genome-wide scale a few studies have been published as to date 
showing high levels of CpG island hypermethylation non-randomly distributed. Using 
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restriction landmark genome scanning (RLGS), Rush et al. could show promoter 
methylation in 8.3% of CpG islands [170]. No studies have however shown a stable 
correlation between DNA methylation patterns and the French-American British (FAB) 
histological AML subtypes with the exception of FAB M3 -Acute Promyelocytic 
Leukemia (APL) [148]. Recent genome wide methylation analyses have confirmed that 
different methylation patterns exist among AML cases that can only partially be 
explained by distinctive molecular and cytogenetic subgroups. Figueroa et al. [148] 
conducted a large scale DNA profiling study of 344 AML samples showing specific 
methylation profiles for each of the core binding leukemias, t(8;21), t(15;17) and inv 16 
as well as CCAT Enhancer Binding Protein-alpha (CEBPA) mutation and silencing as 
well as different profiles for NPM1 mutated cases. Cases harboring 11q23 
translocations also clustered separately in this study, in line with other studies that have 
described a specific methylation profile for Mixed Lineage Leukemia (MLL)-
translocated AML, also elegantly shown by functional experiments by Alvarez et al. 
[171]. The histone methyltransferase activity of MLL, a gene with multiple tranlocation 
partners in 5% of AML, may partially explain this [172, 173].  Interestingly, MLL is 
also a common target for activating partial tandem mutations (PTD) with an incidence 
of 5-11% in cytogenetically normal AML [105]. MLL-PTD mutants retain the 
functional C-terminal SET-domain that has methyltransferase activity. This mutated 
form of MLL is a marker of poor prognosis and has been shown to up-regulate certain 
Homeobox genes by an increase of H3/H4 acetylation [174] and is associated with a 
genome-wide increase in promoter methylation [140]. Furthermore the specific 
methylation pattern seen in APL, characterized by t(15;17), may be explained by the 
activity of the fusion protein PML-RARα which interacts with DNMTs and direct them 
to RARα-targets, causing promoter DNA methylation and gene silencing [175]. The 
oncoprotein PML-RARα has also been shown to interact with other epigenetically 
acting proteins such as HDACs and the Polycomb repressive complex 2 [176, 177]. 
The first line treatment for APL, pharmacological doses of all-trans-retinoic-acid 
(ATRA), dissociates the repressive complexes from the promoter, inducing re-
expression of the silenced genes and concurrent differentiation of the APL cells [175]. 
Similar mechanisms have also been suggested for another fusion protein, AML1-ETO, 
the product of t(8;21), that participates in a protein complex with RARα, recruiting 
DNMTs and HDACs inducing a repressive epigenetic state at these promoter sites 
[178]. EVI-1, overexpressed in inv(3) AML is associated with unfavorable outcome 
and has recently been shown to display a specific genome wide DNA methylation 
signature and interact with DNMT3A and DNMT3B [179]. In other tumor types 
bivalent histone marks as well as Polycomb Group enriched promoters in embryonic 
stem cells have predisposed the promoter methylation patterns seen in cancer [180]. 
There is some evidence that similar mechanisms are active in AML as shown for 
CDKN2B by Zangenberg and Paul et al. [181, 182]. To summarize, some of the 
aberrant methylation patterns seen in AML have molecular explanations. However, 
identification of these as well as identifying which aberrations are driving the disease 
and which are only “passengers” remains a challenge. 
1.3.4.2 Histone modifications 
In contrast to DNA methylation histone modifications have been relatively little 
investigated in AML. On a genome wide level H3K9 trimethylation was investigated in 
AML patients and found decreased at promoter regions. Interestingly, a H3K9me3 
pattern also predicted event free survival in this group of AML patients [183]. There 
were no apparent correlation between H3K9me3 and known cytogenetic aberrations. 
An investigation of the relations between activation (H3K9me3) and repressive 
(H3K27me3) chromatin marks in relationship to DNA methylation of the CDKN2b 
locus on chromosome 9 found that H3K9me3 was lost in samples with DNA 
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methylation of the same loci, but both H3K9me3 and H3K27me3 co-existed, even 
when activating transcription of CDKN2b with 5-aza-2'-deoxycytidine (a DNMT 
inhibitor) and trichostatin A (an HDAC inhibitor)[184]. 
 
1.3.5 Treatment 
1.3.5.1 Current standard treatment 
Most patients younger than 70 years of age receive intensive chemotherapy aimed at 
inducing a complete remission, meaning less than 5% leukemic blasts in the bone 
marrow after recovery after treatment, recovery meaning a neutrophil count of 
>1.0x109/L and a platelet count of >100x109/L[185]. Since the 1970:s the backbone of 
AML-treatment has been a combination of daunorubicin and cytarabine (DA) [186, 
187]. Several different combinations and alternative anthracyclines have been tried, 
none with convincingly better results[188-190], although high dose Daunorubicin 
(90mg/m2) seems to be superior to the previous international norm, 45 mg/m2[191, 
192]. After achieving CR two to three DA consolidation treatments are given often 
including repeated DA courses and/or intermediate/high-dose Ara-C [193, 194]. 
Consolidation with allogeneic stem cell transplantation (allo SCT) in first remission or 
after successful treatment after relapse depends on individual risk stratification. 
Currently all high-risk patients with tolerable co-morbidity below 65-70 years of age 
are eligible for allo SCT in CR1[195]. Intermediate risk patients most likely also 
benefit from allo SCT, at least those with a sibling donor, and several centers already 
practice this for the majority of intermediate risk patients[196-198]. However, the 
prognostic variability in this patient cohort is wide and there is a need of better 
prognostic instruments to select for allo SCT[199-202]. 
1.3.5.2 Epigenetically acting treatment 
There is currently tremendous hope for epigenetically acting therapeutic agents in 
AML, following the landmark analysis that showing a survival benefit of Azacytidine 
in high risk MDS and AML following MDS [203]. In this study patients were 
randomized either to treatment with Azacytidine or conventional therapy including 
high-dose induction or palliative approaches at the treating physicians discretion. There 
was a survival benefit for Azacytidine treated patients where median survival was 24.5 
compared to 16.0 months (p=0.005). Several studies before and after have explored the 
effects of Decitabine and Azacytidine in elderly with high risk MDS and AML, 
however often both de novo AML and AML following MDS have been included. 
Overall response rates have varied from 22% to over 50% with various dosing 
regimens and combinations [204]. Many efforts have been made to find predictive 
markers for success of DNMT-inhibitory therapy but so far none has emerged as a 
stable predictor. There are some indications that demethylating therapy may be more 
effective in high risk MDS with chromosome 7 abnormalities and/or chromosome 5 
abnormalities (excluding del (5q) in MDS)[205, 206], but this finding could not be 
verified in a large retrospective study recently published [207]. Lower baseline 
methylation levels have been suggested to vouch for a better effect of Azacytidine 
[205]. In a recent publication of a phase II trial of Decitabine in older patients with 
previously untreated AML, responders to therapy had higher baseline values of miR-
29b, a micro-RNA that targets DNMT3a and DNMT3b directly and DNMT1 through 
Sp1 and thus lower the global DNA methylation levels[208]. This view is however 
challenged in a recent publication that found no evidence that either global methylation 
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levels or promoter methylation of specific tumor suppressor genes could predict 
response to Azacytidine in combination with the histone deacetylase inhibitor 
Entinostat [209]. 
A multitude of phase I and phase II studies have shown efficacy of DNMT-inhibition in 
MDS [210, 211]. The two FDA approved agents, 5-azacytidine and 5-aza-2’-
deoxycytidine were originally designed as cytosine analogues but later proved to inhibit 
DNMTs, likely have more modes of action than just pure demethylating activity [212]. 
Also supporting this is the lack of correlation between demethylation of specific 
promoters and cell death and that the pattern of gene activation only partially can be 
explained by promoter demethylation[213, 214]. However, as shown in the genome-
wide study by Figueroa et al. there is a gross reduction of promoter methylation already 
at day 15 after treatment start with 5-azacytidine and entinostat, much earlier than blast 
clearance is expected [215]. The slow response to treatment is seen both with 
Decitabine and Azacytidine treatment and does speak against pure cytotoxic effects, 
which usually manifests itself by rapid blast clearance. 
Histone deacetylase inhibitors have also been explored alone or in combination 
regimens for MDS and AML [216, 217]. Phase I studies of Vorinostat (SAHA) and 
MGCD0103 showed effect in a population with mainly MDS and AML patients and 
were well tolerated[216, 218]. As with DNMT inhibitors the mode of action of HDACi 
is not thought to be entirely dependent of epigenetic mechanisms. Even if gene 
reactivation has been shown it seems that at least SAHA works through induction of 
reactive oxygen species [219]. 
In conclusion, neither DNMT nor HDAC-inhibitors have yet found their place in the 
treatment of AML with the possible exception of AML following MDS, where it may 
have merit. However, there is insufficient data to pronounce DNMT-inhibitors superior 
to induction therapy even in that setting. 
 
1.4 CHRONIC LYMPHOCYTIC LEUKEMIA 
1.4.1 Overview and pathogenesis 
Chronic lymphocytic leukemia (CLL) is one of the most common leukemias in the 
western world, characterized by infiltration of morphologically mature small B-
lymphocytes in lymphoid tissue, bone-marrow and blood with a typical 
immunophenotype; CD5+, CD19+, CD23+. The yearly incidence in Sweden is 500, 
and the median age is 72, with a male predominance of roughly 2:1[220]. The 
pathogenesis is not completely known, however a genetic component is likely due to 
the increased incidence in relatives[221]. The CLL cells origins from an 
antigen.experienced B cell with recombination of the V(D)J genes at the Ig locus. 
Approximately 50% of CLL cases also have somatically hypermutated IGHV genes, an 
event that normally takes place in B-cell maturation, perhaps indicating a more 
differentiated cell of origin, in contrast to the 50% of cases with unmutated IGVH 
genes[222]. Since CLL cells are slow growing ex vivo interphase FISH has become the 
method of choice to investigate chromosomal aberrations in CLL. Recurrent 
aberrations can be found in more than 80% of CLL cases; 13q, 17p and 11q deletions 
and trisomy 12 are the most common ones. Deletion 13q is found in approximately 
50%, deletetion of 11q in 20%, 17p in 7% and trisomy 12 in 12% of CLL cases. In 13q 
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deleted CLL cases, the minimally deleted region includes miR-15 and miR-16 which 
were the first micro RNA:s to be shown to be bona-fide tumor suppressor genes in any 
malignancy[223]. One important mechanism of action of miR-15 and miR-16 is that 
haploinsuffiency of these miR:s increases the expression of Bcl-2, critical for tumor 
cell survival[224]. No specific gene/genes have been convincingly implicated as 
oncogenes on chromosome 12. Deletion of 11q often, but not always, includes the 
Ataxia Telangiectasia Mutated (ATM) kinase gene and is also coupled to an inferior 
prognosis[225]. ATM is mutated in 12% of all B-CLL cases and in 30% of del 11q 
cases, which indicates that there may be other tumor suppressor genes in this 
region[226]. Deletion 17p encompasses the TP53 gene and is often accompanied by 
mutation of TP53 on the remaining allele. 
 
1.4.2 Prognostic markers 
1.4.2.1 Clinical staging 
The Rai and Binet clinical staging systems have been used for more than 30 years. 
They are based on the presence of absence of lymphadenopathy, splenomegaly and 
signs of bone marrow failure – anemia and/or thrombocytopenia.  
1.4.2.2 Cytogenetics 
Cytogenetic analysis by FISH is also an important prognostic tool. Deletion of 13q is 
considered to be a good prognostic marker. Trisomy 12 is a sign of intermediate 
prognosis. Deletion 11q has been associated with extensive lymphadenopathy and is a 
poor prognostic marker. Deletion 17p is a marker of extremely poor prognosis. 
1.4.2.3 Mutational status 
IGVH mutational status is also a prognostic factor in CLL. A cutoff at 98% sequence 
homology of IGHVs in CLL with the germline copies of IGHVs is typically used to 
define the separation. However, this is an arbitrary cutoff, and a grey-zone exists; for 
instance those that have a IGHV homology of 95–98%) seem to have an intermediate 
prognosis[227]. 
 
1.4.3  Treatment 
Chlorambucil is an alkylating agent used since more than 50 years in the treatment of 
CLL[228]. With the emergence of newer, more effective agents, the use of 
chlorambucil has declined and nowadays it is usually reserved for elderly patients with 
comorbidity. 
Fludarabine and its family member cladribine are at least as effective as chlorambucil 
as single agent therapy[229], but is preferably used in combinations, especially since 
there is an association between fludarabine single agent therapy and severe immune 
cytopenia[230]. Several combinations of fludarabine have been investigated, and one of 
the most popular at the moment is the combination with the alkylating agent 
cyclophosphamide (FC). Compared with single agent fludarabine both response and 
progression free survival (PFS) was better with the combination, however, overall 
survival (OS) was not increased[231]. Furthermore the incidence of autoimmune 
cytopenias was significantly reduced. The humanized monoclonal antibody 
alemtuzumab is directed at the CD52 antigen, common to normal and malignant B and 
T cells. Compared to chlorambucil it induces better response and PFS, but not OS[232]. 
It seems to have equal effect in 17p deleted patients as it has in others and is thus 
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recommended as first line therapy for 17p deleted cases[233]. It is often used in 
combination with FC, however that combination seems inferior to the combination of 
rituximab (anti CD-20) with FC[234], which is the first combination to achieve 
increased overall survival in CLL[235]. Allogeneic stem cell transplantation remains 
the only potentially curative treatment in CLL. Use is however limited by toxicity and 
it is mainly used in younger, fit patients relapsing after standard therapy or TP53 
mutations[236]. 
 
1.4.4 A p53- micro-RNA- ZAP-70 feedback loop in CLL 
Since the discovery of micro-RNA:s two decades ago the understanding of their 
importance of them in oncogenic transformation and progression has expanded. CLL 
was the first tumor where micro RNA:s could be  shown to play a role via the 
implication of miR-15 and miR-16 in 13q deleted CLL, which was demonstrated both 
by association and with functional studies[223]. Subsequently several micro-RNA:s 
have been shown to be important in other tumors as well as in CLL. A comprehensive 
overview was recently published in JAMA, where a pathogenetic model of the 
involvement of micro-RNA:s and protein coding genes was presented (Figure 6)[237]. 
In CLL samples and cell lines, miR-15 and miR-16 targeted the TP53 gene. In turn, 
expression of p53 induced both miR-15/miR-16 as well as the miR-34b/c clusters, the 
latter in turn targeting and down regulating ZAP-70. In a large group of CLL samples 
levels of p53 were indeed higher in homo or heteroallelic 13q deleted (where the miR-
15/16 cluster is located) samples than in samples with normal karyotype. Also, samples 
with 11q deletions (where the miR-34b/c cluster is located) had lower expression of 
miR-34b then samples with normal karyotype. Conversely, patients with 11q!deletions 
had significantly higher levels of ZAP70 than patients with CLLs with normal 
cytogenetic profiles. Interestingly, the miR-34-family has been implicated in several 
other cancer types, often inactivated by promoter methylation; colon cancer, prostate, 
lung, ovarian, breast, pancreatic, urothelial and renal cell carcinoma [238-240]. 
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Figure 6  The relationship between TP53 inactivation, the miR-34 and miR-15-16 family, ZAP-70, 
BCL2 and MCL1 expression in normal lymphocytes (upper panel) and B-CLL (lower panel). 
Reprinted with permission. 
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A novel pathogenetic model for chronic lymphocytic leukemia (CLL) showing a pathway of microRNAs and
protein coding genes that are involved in the development of CLL. The microRNA 15a (miR-15a)/
microRNA 16-1 (miR-16-1) cluster, the microRNA 34b (miR-34b)/microRNA 34c (miR-34c) cluster, and
the genes tumor protein p53 (TP53), B-cell CLL/lymphoma 2 (BCL2), myeloid cell leukemia sequence 1
(BCL2-related) (MCL1), and zeta-chain (TCR)–associated protein kinase 70kDa (ZAP70) are the main part-
ners in this model. mRNA indicates messenger RNA.
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2 AIMS OF THE THESIS 
2.1 PAPER I AND II 
Principal aim: 
To find AML subsets defined by distinct prognostic DNA methylation signatures. 
Secondary aims: 
To relate these subsets with clinical, cytogenetic and molecular subclasses of AML. 
To find novel tumor suppressor candidate genes. 
 
2.2 PAPER III 
Principal aim: 
To find a second tumor suppressor candidate gene on chromosome 11q23 in CLL apart 
from ATM. 
Secondary aim: 
To relate this tumor suppressor candidate gene´s epigenetic status to response to 
chemotherapy and prognosis in CLL. 
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3 MATERIAL AND METHODS 
3.1 PATIENTS AND TREATMENT 
The World Health Organization 2008 criteria were applied [77] for assessing diagnosis 
and classification of CR and progression. All patients gave informed consent at the time 
of sampling in accordance with the declaration of Helsinki and the respective local 
ethics committee approved the studies. 
 
In paper I a total of 107 previously untreated AML patients treated at the Karolinska 
University Hospital at Huddinge were included. Patients with AML M3 or a previous 
history of MDS were excluded. Standard induction chemotherapy including cytarabine 
and an anthracycline was given aiming at CR. Patients who achieved CR were given 
standard consolidation therapy according to the applicable national or study protocol 
including allogeneic stem cell transplantation. Of all patients reaching CR, 18 (24%) 
received allogeneic stem cell transplantation, 41 (54%) received full consolidation 
therapy and 16 (22%) received reduced chemotherapy consolidation because of 
treatment toxicities. 
 
In paper II primary bone marrow (BM) samples from 118 CN-AML patients were 
obtained at diagnosis from patients at the Karolinska University Hospital, Huddinge 
(n=55), Uppsala University Hospital (n=15), Örebro University Hospital (n=9), Ulm, 
Germany (n=10) and Angers, France (n=29). Patients with AML M3 or a history of 
MDS or MPD or previous chemotherapy were excluded. Standard induction 
chemotherapy including cytarabine and an anthracycline was given aiming at CR. 
Patients who achieved CR were given standard consolidation therapy according to the 
applicable national or study protocol including allogeneic stem cell transplantation 
which was performed in 39 (33%) of the patients. 
 
In paper III peripheral blood from 66 CLL patients from Uppsala University Hospital 
(n=60) and Karolinska University Hospital, Huddinge (n=6) was collected. Various 
therapy regimens were delivered as deemed fit by the treating physician. No patient 
underwent allogeneic stem cell transplantation. 
 
3.2 NORMAL CONTROLS 
In paper II, bone marrow from nine healthy controls was collected, all with informed 
consent in accordance to the declaration of Helsinki and approved by the ethics 
committee.  
 
3.3 INCUBATION OF CELLS 
In paper III CLL and normal cell incubations as well as the HG3 CLL cell line 
incubations were performed in RPMI Medium 1640 with Glutamax and HEPES buffer 
(Invitrogen) with 10 % FBS added. 3-5 million cells were incubated for 48 hours in 
37°C at a cell density of 300.000 cells/ml in 5µM 5-aza-2-deoxycytidin (Decitabine) 
and 0.1 µM doxorubicin and 1 µM Prima-1. 
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3.4 CELL SEPARATION AND STORAGE 
All AML samples were separated for mononuclear cells by density gradient 
centrifuging (Lymphoprep; Axis-Shield PoC). In cases when DNA was not extracted 
immediately, cells were vital frozen in -150°C. BM from healthy donors (n=9) was 
separated for mononuclear cells by Lymphoprep (Axis-Shield). BM CD34+ cells were 
further separated by MACS, indirect CD34 microbead kit (Miltenyi Biotec), according 
to the manufacturer’s instructions. In five cases, the common myeloid progenitor 
(CMP) and granolucyte- macrophage progenitor (GMP) cells were purified from the 
CD34+! pool with FACS, using antibodies specified in supplemental Table 4 as 
previously described[241] and CD34+ cells were used in four cases. 
  
CD38 FITC  
CD110 PE  
CD123 PerCP Cy5.5 
CD33 PE Cy7 
CD34 APC  
CD45RA Pacific Blue.   
CMP;  CD38+, CD34+, CD123+, CD110 
, CD45RA+ 
GMP; CD38+, CD34+, CD123+, CD110 
, CD45RA 
Table 4 Antibodies used to separate CMP and GMP stages in paper II. 
CLL cells were collected from peripheral blood from CLL patients and contained 
>70% lymphocytes according to immunophenotyping. Normal lymphocytes were 
collected from healthy volunteers and from mixed leukocyte DNA from multiple 
donors (Roche, Bromma, Sweden). CD19+ normal leukocytes were purchased from 3H 
Biomedicals (Uppsala, Sweden). CLL and normal cell incubations as well as the HG3 
CLL cell line incubations were performed in RPMI Medium 1640 with Glutamax and 
HEPES buffer (Invitrogen) with 10 % FBS added. 
 
3.5 NUCLEIC ACID SEPARATION 
DNA was separated using the DNeasy kit (Qiagen, Valencia, CA, USA) or the 
QuickGene kit (Fujifilm, Stockholm, Sweden). RNA was extracted using the RNeasy 
kit (Qiagen) according to instructions, and quality was controlled using an Agilent 
Bioanalyzer (Agilent Technologies). DNA was stored in -20°C and RNA in -80°C. 
 
3.6 MOLECULAR, IGVH AND FISH ANALYSES 
Mutation analyses of FLT3 (internal tandem duplications and tyrosine kinase domain 
mutations at codon D835 and I836) and NPM1 were performed by the Döhner 
laboratory in Ulm as previously described[109, 131]. IDH1 and IDH2 (exon 4) were 
also investigated in Ulm. Briefly, DNA fragments spanning the entire exon 4 of IDH1 
and IDH2 were amplified by polymerase chain reaction (PCR) by using Optimase 
Polymerase (Transgenomic, Glasgow, United Kingdom) and gDNAs as templates. 
IDH1 and IDH2 amplicons were screened for heterozygous mutations by using 
denaturing high-performance liquid chromatography (dHPLC) on a WAVE 3500HT 
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DNA Fragment Analysis System (Transgenomic). The individual dHPLC 
chromatograms were compared with a wild-type reference; samples that differed from 
the wild-type reference were reamplified in an independent PCR reaction and were 
assessed for sequence variations by direct sequencing or sequencing after subcloning. 
For CEBPA, complementary DNA (cDNA) was generated from 1 µg of mRNA using 
SuperScript reverse transcriptase (Invitrogen, Carlsbad, CA). The CEBPA coding 
region was divided into three overlapping amplicons. After PCR amplification, 10 µl of 
PCR product was mixed with 10 µl of corresponding PCR product obtained from NB4 
cell line cDNA. Heteroduplexes were allowed to form in an Applied Biosystems 
(Foster City, CA) GeneAmp PCR System 9700 (2 cycles of 95°C for 3 minutes, cooled 
to 220°C with a ramp of 5%, and maintained at 20°C for 5 minutes). The samples were 
then subjected to dHPLC analysis. Samples with aberrant peaks were subjected to 
direct nucleotide sequencing on an Applied Biosystems 3100 device using the forward 
and reverse primers. In case a mutation was found, a second analysis on new input 
material was performed to rule out PCR-induced artifacts. In AML cases for which 
dHPLC had revealed one single heterozygous mutation, the CEBPA coding region was 
fully sequenced to exclude the possibility that a second mutation had gone unnoticed. 
Detailed protocols including primer sequences are available online[131, 242]. 
IgHV mutational status was investigated by PCR amplification and sequencing as 
previously described[243]. Briefly, VH gene family-specific polymerase chain reaction 
(PCR) amplification was performed as previously described[244]. In the majority of 
samples clonal PCR products were sequenced directly using the BigDye Terminator 
Cycle Sequencing Reaction Kit (Perkin-Elmer, ABI, Foster City, CA), but in 13 cases 
cloning of the PCR products was performed as described elsewhere[244]. The 
sequences were aligned to IgH sequences from the BLAST, V-BASE, and IMGT 
databases. VH gene sequences deviating more than 2% from the corresponding 
germline gene were defined as mutated. The distribution of replacement mutations and 
silent mutations within the CDRs and framework regions was assessed according to the 
multinomial distribution model published by Lossos and colleagues to determine the 
extent of antigen selection in mutated VH genes[245]. The length of the CDR3 was 
calculated between codon 95 and 102. 
Interphase FISH analysis was performed on CLL samples for del(13q) (D13S319, 
LAMP1), del(11q) (ATM), trisomy 12 (centromere), and del(17p) (TP53) using 
commercial probes from Abbot Vysis (Stuttgart, Germany) as previously 
described[225]. Two-hundred interphase nuclei were analyzed for each probe and 
sample. The cut-off level for samples to have a particular aberration was 10%. 
 
3.7 BISULFITE CONVERSION AND DNA METHYLATION ANALYSES 
Bisulfite conversion was performed manually in paper I as previously described[246]. 
Briefly, 2.5mg of DNA from each sample was denatured in NaOH for 15 min at 37 1C, 
followed by incubation in sodium bisulfite at 551C for 16h. Thereafter, DNA was 
recovered using the GeneClean II kit (Qbiogene, Montreal, QC, Canada), desulfonated 
in NaOH and precipitated in ethanol. The EZ DNA methylation kit (Zymo Research) 
was used for bisulfite conversion of 500-1000 ng of DNA per sample in papers 2 and 3. 
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3.7.1 Methylation specific melting curve analysis 
The method was developed by professor Guldberg in Copenhagen and is described in 
detail previously[247]. PCR of the promoter region was performed with SYBR green-
containing master mix. Immediately after amplification, a melting curve was produced 
and compared to a positive (SSS1 treated DNA, Roche) and negative control (Mixed 
Human Leukocyte DNA, Invitrogen). Samples with right shifted melting curves 
compared to the negative controls were considered methylated. Primers were designed 
using the Oligo1.0 software (Molecular Biology Insights, Cascade, CO, USA) for MS-
MCA and primer sequences are given in the paper, supplementary table I. 
 
3.7.2 Denaturing gradient gel electrophoresis (DGGE) 
The method has been described in detail previously[248]. In brief, the PCR products 
were loaded on a 10–70% denaturant gradient gel together with a fully methylated 
control (In vitro methylated DNA) and an unmethylated control (peripheral blood 
lymphocytes). After electrophoresis, gels were stained in Tris/EDTA buffer containing 
ethidium bromide and photographed under ultraviolet transillumination. Samples were 
scored as methylated when bands or smears were present on the gels in the area below 
the band corresponding to unmethylated DNA as reported in previous 
publications[248]. 
 
3.7.3 Luminometric assay (LUMA) 
Global DNA methylation was quantified by luminometric assay (LUMA) as previously 
described[249, 250]. A total of 500 ng genomic DNA was cleaved with HpaII plus 
EcoRI or MspI plus EcoRI in separate reactions. After the digestion step, the extent of 
cleavage was quantified by pyrosequencing. HpaII and MspI are methylation-sensitive 
isoschizomers. DNA methylation is assessed by the HpaII/MspI ratio. 
 
3.7.4 Bisulfite pyrosequencing 
Bisulfite pyrosequencing was performed for the CDKN2A, CDH1, HIC1, and 
CDKN2B promoter. After bisulfite conversion pyrosequencing was performed on the 
PyroMark12 platform (QIAGEN) as previously described.12 Primer sequences and 
PCR conditions are available at: www.techsupport.pyro sequencing.com. Samples were 
in general considered as methylated at mean levels of more than 15% methylation. 
 
3.7.5 DNA methylation arrays 
Genome-wide DNA methylation profiling was performed using the Illumina Infinium 
HumanMethylation27 BeadChip (Illumina) for 20 samples in paper I and 89 samples in 
paper II, of which 29 were performed in Angers, France and the rest at the BEA core 
facility at Novum, Karolinska Institutet. Upon treatment with bisulfite, unmethylated 
cytosine residues are deaminated to uracil while methylated cytosines remain 
unaffected. The assay interrogates these differentiated loci using two site specific 
probes, one designed for methylated residues and one for unmethylated. Single-base 
extension of the probes incorporates a biotin labelled ddNTP, which is subsequently 
stained with a fluorescence reagent in order to determine the signal intensities of 
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methylated vs unmethylated probes. The EZ DNA methylation kit (Zymo Research) 
was used for bisulfite conversion of 500-1000 ng of DNA, and the remaining assay 
steps were performed as previously published, using Illumina-supplied reagents and 
conditions[251]. The readout from the array is a β-value, which is defined as the ratio 
between the fluorescent signal from the methylated allele to the sum of both methylated 
and unmethylated allele and thus correlates to the level of DNA methylation. A β-value 
of 1.0 corresponds to complete methylation and 0 equals no DNA methylation.  
 
3.8 GENE EXPRESSION ANALYSES 
Whole genome expression arrays were performed by the BEA core facility at the 
Karolinska Institute using the Illumina HumanHT-12 Version 4 Expression BeadChip 
using the Direct Hybridization Assay and iScan system (Illumina). Details of the 
procedure can be accessed online: 
http://www.illumina.com/products/humanht_12_expression_beadchip_kits_v4.ilmn 
Quantitative RT-PCR was performed using primers, control genes and PCR conditions 
as described in each paper. 
 
3.9 CHROMATIN IMMUNOPRECIPITATION 
Chromatin Immunoprecipitation (ChIP) in paper III was performed using Magnetic 
LowCell ChIP kit from Diagenode (Denville, NJ, USA) according to manufacturer’s 
instruction, using antibodies against H3K27me3 (Abcam, ab6002), H2Az (Abcam, 
ab4174) and H3 (Abcam, ab1791) for normalization as previously described[252]. 
 
 
3.10 STATISTICAL ANALYSES 
Categorical clinical parameters and gene-specific variables were analyzed in relation to 
CR by chi-square analyses or Fisher’s exact test as appropriate. In paper I, the 
contribution of gene promoter methylation and global methylation to DFS and OS were 
assessed using the Kaplan–Meier method and compared with the log-rank test. Binary 
logistic regression was used for multivariate analysis of CR. Cox regression analysis 
was used for multivariate analysis of DFS and OS. Testing for proportional hazards 
was performed by plotting the log of hazard for each included variable from the 
Kaplan-Meier curves against time. Correlations were calculated with Pearson’s 
correlation for continuous variables and Spearman’s rho for ordinal data. Multiple-
group comparisons were made using one-way analysis of variance. In paper II 
statistical analysis of the methylation array data was carried out in the statistical 
computing language R (www.r-project.org). To search for the differentially methylated 
genes between the different prognostic subgroups, the data were arcsin transformed and 
an empirical Bayes moderated t test was then applied using the “limma” package. The 
P values were adjusted using the method of Benjamini and Hochberg and a level of P 
less than 0.05 was used as a cut-off. An additional filter for the average geometric 
difference was also applied to assure only genes with absolute differences of more than 
β 0.10 between the groups remained. Integration of gene expression array data with 
methylation array data and integration of previously published ChIP-chip results were 
made with the BeadStudio Version 3.2 software (Illumina). Unsupervised hierarchical 
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clustering analysis and principal components analysis were performed with the Genesis 
software package 17.1. Hierarchical clustering analysis distance was measured using 
Pearson correlation with a complete clustering algorithm. Samples were normalized 
using a global mean centering method. Methylation levels of different molecular 
subgroups were measured as continuous variables. Hypermethylation of individual 
CpG sites was defined as β -values more than 0.7, unmethylated as β less than 0.3, and 
values in between were called “methylated”. Differences in overall and progression free 
survival was evaluated using the Log-Rank test after construction of Kaplan-Meier 
curves. Multivariable analyses were performed using Cox Regression analysis for 
survival and Logistic regression for remission rates. In paper III differences in 
expression between groups were calculated using the Students T-test or the Mann-
Whitney test when appropriate and the relationship between promoter methylation and 
cytogenetic aberrations or IgVH status by the Chi-square test. SPSS versions 16-20 
(IBM) were used for statistical calculations. 
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4 RESULTS AND DISCUSSION 
4.1 GLOBAL DNA METHYLATION IS INVERSELY CORRELATED WITH 
CPG ISLAND METHYLATION 
In paper I and paper II samples were investigated with LUMA, which is a surrogate 
marker for global 5-methylcytosine content. In paper I twenty samples were also 
investigated with the IlluminaHuman27 methylation bead array, an array with a strong 
bias towards promoter regions and CpG islands. The relationship of global methylation 
as measured by LUMA was found to be inversely correlated with the number of 
hypermethylated CpG sites in the Illumina array (defined as β>50%), Pearson 
correlation 0.627, P=0.003 (figure 7, upper panel). The results were corroborated in 
paper II where 29 samples were investigated by both methods and the Pearson 
correlation was -0.45, P=0.02 (figure 7 lower panel). The reason for the inverse signs of 
the correlation coefficients was that LUMA methylation was calculated differently in 
the two publications; HpaII/MspI in paper I and 1-(HpaII/MspI) in paper II. 
 
 
Figure 7 The upper panel shows the relationship between global methylation measured by LUMA 
and Illumina array methylation for 20 samples from paper I. R=0.627, P=0.003. The lower panel 
show the same relationship for 29 samples from paper II. R=-0.45, P=0.02. See text for details. 
 
 
confirmed the association between p15 methylation and
survival (data not shown). HIC1 methylation showed no statis-
tically significant association with CR. OS was better in HIC1
methylated cases in univariate analysis (median 23 vs 11
months), but there were no statistically significant associations
between HIC1 methylation and OS or DFS in multivariate
analysis (data not shown). There were no differences in clinical
outcomes between patients with methylated and unmethylated
CDH (data not shown).
Increased genome-wide promoter hypermethylation is
associated with better DFS and OS
As our results suggested that increased gene-specific methyla-
tion of the p15 promoter is associated with better outcome, we
also analyzed whether genome-wide promoter hypermethyla-
tion was associated with CR rate, DFS or survival. Cases were
dichotomized at median into two groups by the number of
hypermethylated (b40.5) CpG sites according to the Illumina
array. There were no significant differences in age, cytogenetic
or molecular risk factors between the groups. CR rates did not
differ between the groups, but the DFS was significantly longer
in patients with more hypermethylation, with median not
reached compared with 4 months for cases with less hyper-
methylation (P¼ 0.02; Figure 4c). The median OS was not
reached compared with 6 months (P¼ 0.005; Figure 4d). These
results suggest that not only increased p15 promoter methyla-
tion, but also genome-wide promoter-associated hypermethyla-
tion in general is associated with improved survival.
Associations between methylation status and genetic
abnormalities
We also studied the relation between gene-specific methylation
as well as global methylation by LUMA in relation to molecular
and cytogenetic status of the AML cells. Table 3 shows the
results in patients subdivided according to cytogenetic and
molecular status. Although some associations could be shown,
after Bonferroni correction, all associations were found to be
nonsignificant.
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Figure 2 Illumina HumanMethylation27 array results and comparison with global LUMA methylation. (a) The average number of CpG sites
methylated at different b-values in the whole cohort shows a bimodal distribution. The b-value is a measure of the degree of methylation, and
higher means more methylation. (b) Correlation between the number of Illumina hypermethylated (b40.5) CpG sites and LUMA global
methylation level in each patient analyzed by both. Pearson’s correlation 0.627, P¼0.003. Increasing LUMA values indicate less global
methylation. (c) Volcano plot showing more Illumina global CpG site methylation in the group with low global LUMA methylation (dots positive
on the x axis) and less in the high global LUMAmethylation group (dots negative on the x axis). The dotted lines indicate 0 and±2 times difference
between groups on a log2 scale, P-value of t-test statistics is indicated on a log10 scale on the y axis.
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methylated in normal progenitors than in AML samples. DMC 3
and DMC 4 were more methylated in progenitors than in AML
(Figure 4B). A principal components analysis of the same CpGs
clearly separated clusters 1 and 2 from 3 and 4, confirming their
relevance. However, DMC 1 and DMC 2 separated only on the
z-axis, as did DMC 3 and 4 (Figure 4C). On the whole array, 72.5%
of all CpG residues are located in CpG islands. In comparison,
DMC 1 consisted overwhelmingly of CpG residues within CpG
islands, 95% (P ! 1E-40), whereas in DMC 3 and DMC 4, only
24% and 29% of the CpG residues were located in CpG islands,
respectively (P " 1E-65 for both). DMC 2 had a slight increase in
the proportion of CpG island-annotated sites, 80% (Figure 4D).
Gene ontologic analyses showed that DMC 3 and DMC 4 were
enriched for genes involved in defense responses, DMC 1 and
DMC 2 for genes related to cell-cell signaling, neuron differentia-
tion, embryonic morphogenesis, and cell fate commitment, mainly
homeobox (HOX) genes (supplemental Table 4). The average
#-values of the differentially methylated CpG sites were higher in
Figure 1. (A) Average #-levels for 15 to 17 samples (y-axis) according to bisulfite pyrosequencing results. Bisulfite pyrosequencing was considered methylated at a cut-off of
15%. P ! .03, .01, and .06 for CDKN2B, HIC1, and CDH1, respectively. There were no methylated samples of CDKN2A according to bisulfite pyrosequencing. (B) Technical
replicates; 2 samples were replicated on the 27k array (top panel) and 2 replicates on both the 27k and 450k array (bottom panel). All were highly correlated (P " .0001) with
Pearson correlation coefficients of r ! 0.99, 0.94 and r ! 0.98, 0.98, clockwise from top left. (C) There is an inverse relationship between promoter methylation assessed by the
Illumina HumanMethylation27 array and global CpG methylation as measured by LUMA (Pearson r ! $0.45, P ! .02, n ! 29).
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Our interpretation of this is that we have found that in AML, CpG islands in general 
become methylated while non-CpG-island DNA becomes hypomethylated and that the 
extent of these changes correlate. This conclusion relies on the validity of our methods. 
Do we actually measure global, non CpG-island methylation with LUMA? We believe 
that it does. Since LUMA analysis is based on the HpaII/MspI recognition sequence, 5’ 
-CCGG-3’  which are fairly well interspersed through the genome- approximately 50% 
of the CCGG sites are located in repetitive DNA sequences and 50% in unique 
sequence[253], and even though they are accumulated at CpG islands, CpG islands 
only comprise about 1% of the genome[254]. On the contrary, of the 27578 CpG sites 
on the Illumina HumanMethylation 27k array, 97,7% interrogates CpG sites within 
1500 bp from the transcription start site. Even if this finding is novel in AML, the 
inverse relationship has been described in several other tumors[255, 256]. A recent 
bisulfite sequencing study of colon cancer found the same phenomenon and also in 
detail could describe the loss of homeostasis of DNA methylation in cancer compared 
to normal tissue[155]. The most common finding was disintegration of the boundary 
between low methylation in CpG islands and high methylation in surrounding DNA, 
resulting in a smoothening effect with hypomethylation of non CpG island DNA and 
hypermethylation of CpG islands, occurring in “blocks”. Although yet to be verified in 
AML with bisulfite pyrosequencing, these results are fully compatible with our 
findings. 
 
4.2 GLOBAL DNA METHYLATION MEASURED BY LUMA CORRELATE 
WITH CLINICAL OUTCOMES 
In paper I we found a borderline significant correlation between low global methylation 
levels by LUMA and CR rate (P=0.05). In subset analyses, the correlation seemed to be 
limited to patients younger than 65 years of age (P=0.02), where low global 
methylation also translated to improved overall and disease free survival (figure 8). The 
reason for the increased CR rates in patients with global hypomethylation observed in 
our study is unclear. It is significant in multivariate analysis, but the genes most 
differentially methylated between patients achieving CR and those not achieving CR 
are different from the genes governing overall and disease free survival. In paper II, 
where we had access to genome wide methylation status of a larger cohort, we found 
that there were several interesting genes among those most significantly associated with 
CR, for instance; glutathione transferase (GSTP1), a gene central to protection against 
oxidative stress and xenobiotics as well as implicated in anti-cancer drug 
resistance[257-259]. Promoter methylation of GSTP1 is an independent factor for 
increased anthracycline chemosensitivity in breast cancer[260].  MMP-7, a matrix 
metalloproteinase, has been shown to inhibit anthracyclin induced apoptosis while 
silencing of MMP-7 with antisense cDNA increased sensitivity[261]. Targeting MMP-
7 with inhibitors has proven efficacious in inducing chemosensitivity in various tumor 
models[262]. DHH[263], LCP-1[264, 265], TRAF-1[266] are other genes implicated in 
chemoresistance that were found to be significantly more methylated in patients 
achieving CR and inversely correlated to global methylation by LUMA.  
There were somewhat fewer patients with adverse and more with favorable karyotype 
in the hypomethylated group, but these differences were not significant in multivariate 
analysis. One explanation of the limitation of the effects to younger patients could be 
that intra-individual methylation variation accelerates with increasing age, which could 
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affect both global and gene-specific methylation and hence make cross-sectional 
analyses such as ours less predictive in an older population[254, 267]. Another 
explanation may be that AML in older subjects actually is an epigenetically different 
disease, perhaps more similar to MDS where disrupted DNA methylation patterns in 
general is a degenerative phenomenon and a bad prognostic sign[166, 215]. 
 
Figure 8 CR rates are higher in patients whose samples show global hypomethylation. The pie 
charts show CR rates in samples with global methylation levels higher than median (‘global DNA 
hypermethylation’) and global methylation levels lower than median (‘global DNA 
hypomethylation’). (a) The whole AML cohort (P=0.05), (b) the same data for AML patients 
younger than 65 years (P=0.02) and (c) for AML patients older than 65 years (P=0.7). (d) Overall 
survival (P=0.9) and disease-free survival (P=0.6) in the whole AML cohort according to high or 
low global DNA methylation by LUMA. (e) In patients younger than 65 years, OS (P=0.005) and 
DFS (P=0.04) were significantly better in samples with low global LUMA methylation levels. 
Patients were censored at the time of allogeneic stem cell transplantation. 
 
 
Discussion
The role of DNA methylation in AML remains unclear. Studies
on how methylation of gene promoters correlates with clinical
outcome as well as with genetic and other clinical character-
istics are few and data are somewhat conflicting.9,22 Exploration
of the epigenetic patterns in AML has the potential to define new
biological subgroups of AML or to provide new prognostic
biomarkers. In the light of the emerging therapeutical field of
epigenetically acting drugs, basic knowledge about methylation
in leukemia is necessary to use these drugs efficiently and for
rational study design. In this study we have analyzed the r le of
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4.3 METHYLATION OF CDKN2B MEASURED BY DGGE CORRELATES 
WITH IMPROVED SURVIVAL IN AML 
In paper I, DNA methylation analysis by DGGE showed methylation of the CDKN2B 
(p15) promoter in 66%, of CDH in 66% and HIC1 in 51% of the evaluable AML cases. 
Only p15 and HIC1 methylation correlated with each other (R=0.33, P=0.001) and only 
p15 methylation associated with overall and disease free survival, but not CR rate 
(figure 9). 
 
Figure 9 Kaplan–Meier diagrams showing the prognostic effect of CDKN2B (p15) promoter 
methylation by DGGE on (a) disease-free survival (n=104) and (b) overall survival (n=78) 
  
The DGGE analysis was validated by bisulfite sequencing of the p15 gene promoter, 
which was concordant in 23/29 samples evaluated with both methods (79%, P=0.003 
Chi2) and with MS-MCA in nine samples, which were 100% concordant. Previous 
studies evaluating the relationship between methylation of the p15 promoter and 
survival in AML show conflicting results. Methylation of the p15 promoter has been 
associated with poor prognosis[160, 268, 269] whereas some studies have failed to 
show any association with prognosis[270, 271]. Other studies support our findings, 
associating more methylation with better prognosis in AML[272]. This concept has 
been shown previously in colon cancer, in which the CpG island methylated phenotype 
subtype is associated with improved survival[273]. We believe that the diverging 
results between our findings and the studies mentioned above are due to differences in 
the selection of patients and methylation analysis techniques. Recent data, including 
our own observations, have illustrated the differences between MDS, MDS–AML and 
de novo AML regarding methylation patterns [166, 215, 274], and we suggest them to 
be analysed separately. There is no information of the frequency of MDS related or 
secondary AML cases in the study by Shimamoto et al, and in the study by Wong et al, 
the adverse risk of p15 promoter methylation in the adult AML subset was actually not 
significant (P=0.145)[269]. The recent study by Alvarez et al. utilized Illumina Golden 
Gate array technology validated with methylation specific-PCR (MS-PCR) found that 
p15 promoter methylation was an adverse prognostic factor, however not retained in 
multivariable analysis[160]. We believe that the use of MS-PCR, as for instance by 
Shimamoto et al.[268], is problematic. DGGE is less sensitive than methylation-
specific PCR but most likely better reflects the general methylation levels in the highly 
variable promoter region[275]. In addition, methylation-specific PCR may pick up very 
low levels of methylation that are not physiologically relevant. Even so, we believe that 
p15, HIC1 and CDH methylation, as well as that of global DNA
methylation, in a large cohort of genetically and clinically well-
defined AML patients undergoing induction chemotherapy. The
analysis was performed to study the effect of methylation on
clinical outcome and response to therapy as well as its relation
to genetic subtypes of AML. We also performed an analysis of
genome-wide promoter-as ociat d methylation using Illumi a
HumanMethylation27 BeadChip array technology in a subset of
20 patients.
Important novel observations in this study are the associations
between global DNA methylation as well as p15 promoter
methylation and clinical outcome. Other novel findings were
the prognostic significance of the number of hypermethylated
CpG sites as measured by Illumina Infinium for DFS and OS as
well as the inverse association between global DNA methylation
and genome-wide promoter methylation.
Our data suggest the existence of a subset of AML cases with
good prognosis, characterized by low global DNA methylation
levels paired with increased p15 methylation as well as genome-
wide promoter-associated methyla ion levels, mainly discern-
able in younger patients.
Global DNA hypomethylation is a common phenomenon
in cancer4,23 and an indicator of good prognosis in acute
lymphoblastic leukemia,24 whereas it is a poor prognostic
marker in breast cancer.25 In AML, a decrease in global DNA
methylation at relapse compared with diagnosis was observed in
one study; however, these patients were selected on the grounds
of having relapsed, which makes comparisons with our study
difficult.26 Mechanistically, global DNA hypomethylation may
have a role in cancerogenesis through increased genomic
instability, activation of oncogenes or retrotransposons.27 The
reason for the increased CR rates in patients with global
hypomethylation observed in our study is unclear. There were
somewhat fewer patients with adverse and more with favorable
karyotype in the hypomethylated group, but these differences
were not significant and were not retained in multivariate
analysis. Recent data show increased global LUMA methylation
in cell lines resistant to daunorubicin in comparison to their
sensitive counterparts (own unpublished d ta), suggestive of a
possible association with drug resistance. Further studies on this
matter are warranted, especially to determine whether demethyl-
ati g agents could sensitize resistant cells to conventional
cytostatic drugs in AML, which has already been shown in vitro
in other cancers.28,29 Furthermore, our analysis showed that
global LUMA methylation data were prognostically important
mainly in patients younger than 65 years. One explanation for
this could be that intra-individual methylation variation accel-
erates with increasing age, which could affect both global and
gene-specific methylation a d hence make cross-sectional
analyses such as ours less predictive in an older population.30,31
Differences in correlations with CR versus survival for prog-
nostic factors are not uncommon in AML. Although obviously
correlated, CR and survival represent somewhat different effects
on the disease, which may explain the differences in outcome
on these variables. We also found an inverse relationship
between global methylation levels as measured by LUMA
and CpG island-related genome-wide methylation levels as
measured by Illumina HumanMethylation 27. LUMA analysis is
based on the HpaII/MspI recognition sequence, 50-CCGG-30,
which are fairly well interspersed through the genome. Approxi-
mately 50% of the CCGG sites are located in repetitive
DNA sequences and 50% in unique sequence,32 and even
though they are accumulated at CpG islands, CpG islands only
comprise about 1% of the genome.31 Therefore, methylation
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further studies of the relevance of p15 promoter methylation on prognosis in AML are 
needed before the matter is resolved. 
 
4.4 GENOME WIDE METHYLATION PATTERNS MEASURED WITH 
ILLUMINA ARRAYS ASSOCIATE WITH SPECIFIC MOLECULAR 
MUTATIONS IN CN-AML 
In paper II, 58 cases of CN-AML were investigated with Illumina 
HumanMethylation27k arrays. To find differentially methylated CpG sites, we applied 
a Bayes modified, Benjamini-Hochberg adjusted t-test for difference set to less than 
0.05 and a minimum geometric average distance between groups of β >0.10. With these 
criteria, 2764 CpG residues corresponding to 2304 genes were found to be 
differentially methylated. Unsupervised hierarchical clustering of the samples based on 
these was performed showing six sample clusters with unequal distribution of NPM1 
and IDH mutations (P=0.01 and P=0.0001, respectively, Fisher-Freeman-Halton test). 
Results are shown graphically in figure 10. 
 
Figure 10 Unsupervised complete linkage hierarchical clustering of samples according to 
methylation of the 2764 differentially methylated CpG sites. There are 2 outliers and 6 major 
clusters of samples. The normal samples clustered together within cluster one (grey) and are 
marked by grey boxes below the dendrogram. Mutational status is indicated below; white boxes 
represent wild-type; and colored boxes, mutations. P values are given for unequal distribution 
between clusters for each mutation using the Fisher-Freeman-Halton test (outliers were 
disregarded). The frequency of NPM1 mutations is increased in cluster 2 and 6, IDH1 in cluster 6, 
and IDH2 in cluster 2. 
 
The clustering according to different mutations is not surprising and has been described 
in another well performed study[148]. Interestingly, IDH1 and IDH2 mutations 
clustered in different groups, and in univariate analysis both were associated with 
increased average β-levels (p=0.006), but in IDH1 mutated samples, only CpG-island 
annotated sites showed increased methylation (P=0.02), whereas in IDH2 mutated 
samples, only non-CpG island sites were hypermethylated (P=0.0002). Furthermore, 
Polycomb Group (PcG) associated targets were preferably methylated in IDH1 mutated 
compared with IDH2 mutated samples. The mechanistic link behind this is not clear. 
However, IDH1 is a cytosolic enzyme and IDH2 mitochondrial[276], making it 
most AML samples compared with normal progenitors (P ! .0003;
Figure 4E). However, the individual AML samples showed a great
variability from close to normal to extreme hypermethylation. To
confirm our findings, we repeated the hierarchical clustering and
gene ontologic analyses in the validation AML cohort and normal
controls with similar results as in the test cohort: 4 major clusters
with similar gene ontologic enrichment as in the test cohort (data
not shown).
Polycomb target genes and genes with bivalent histone marks
in stem cells are preferably methylated in CN-AML
It has been reported that genes in stem cells associated with PcG
transcriptional repressor proteins become hypermethylated in
various solid tumors.22,23 To investigate this on a genome-wide
scale in AML, we integrated chromatin immunoprecipitation
sequencing (ChIP-seq) data of Polycomb repressor complex 2
(PRC2) proteins in human embryonic fibroblasts by Bracken
and Helin23 with our own methylation data. We recorded the
difference in "-values between AML samples in the test cohort
(n ! 58) and normal progenitor cells (#") for every CpG
residue present on the Illumina array and compared #" for all
CpGs annotated to the genes implicated as PcG targets in the
ChIP-seq dataset with those that were not. Indeed, PcG target
genes in the Bracken and Helin study23 had a greater increase in
methylation (#", 0.09 vs 0.05, P $ .0001). The difference was
restricted to CpG islands (#", 0.08 vs 0.02, P ! 1.9E-144),
whereas in non-CpG island residues, there was actually a slight
but significant decrease of methylation in PcG-associated genes
(#" 0.12 vs 0.13, P ! .005; Figure 5A). Furthermore, PcG
target genes in human embryonic fibroblasts were 2- to 4-fold
more common in DMC 1 and DMC 2 (OR ! 3.5; 95% CI,
3.0-4.1; and OR ! 2.1; 95% CI, 1.7-2.4, respectively, P $ 1E-20
for both, Figure 5B). Interestingly, PcG-targeted genes were
significantly more common among hypermethylated genes in
IDH1-mutated versus nonmutated samples (33% vs 17%,
P ! 3E-8), whereas in IDH2-mutated samples they were not
(19 vs 17%, P ! .10). There was a clear association between
DNA methylation and silencing also in PcG-targeted genes
(Figure 3C).
The PRC2 catalyzes the trimethylation of lysine 27 on
histone H3 (H3K27Me3). Concurrent methylation of lysine 4 on
histone H3 (H3K4Me) coincides with H3K27Me3 at transcrip-
tion factors important for developmental control in stem cells.24
The relevance of such “bivalent marks” was investigated by
applying ChIP-seq data of bivalently marked genes from a study
in hematopoietic stem cells by Cui et al in a similar fashion as
described for PcG targets above.25 #" was greater among genes
with bivalent marks (#", 0.08 vs 0.05, P $ .0001), again
restricted to CpG islands (#", 0.08 v 0.01, P $ .0001,
Figure 5C). Among non-CpG island residues, there was a slight
decrease of methylation of bivalently marked genes (#", 0.11 vs
0.13, P ! .006). As for PcG targets, genes with bivalent marks
were enriched in DMC 1 and DMC 2 (OR ! 5.3; 95% CI,
4.6-6.2; and OR ! 2.3; 95% CI, 2.0-2.6, respectively, P $ 1E-20
for both, Figure 5B). Similar results were attained when using
gene sets from LIN1- hematopoietic stem cells with bivalent
arks26 as well as ChIP for the PRC 2 protein SUZ1227 (data not
shown). PcG target genes and genes with bivalent marks were
significantly overlapping. Overlapping genes and genes that
were PcG targets but not bivalently marked had similar #"-
values (P ! .8), which was higher than for genes with bivalent
marks that were not PcG targets (P $ .0001, Figure 5D).
Promoter methylation and prognosis
The CpG sites that were most significantly coupled to CR and
2-year survival were selected by a Bayes moderated t test (adjusted
P $ .05, geometric difference % 0.10 beta). Of the 42 CpG sites
most significantly coupled to CR in this supervised analysis, 38%
were hypermethylated (ie, "-values % 0.6) in patients achieving
CR and 18% among patients who did not (P ! .0002; Figure 6A;
supplemental Table 5). Similarly, of the 62 CpG sites most
significantly correlated to 2-year survival, 64% were hypermethy-
lated in the group of patients that achieved 2-year survival
compared with 30% in the group who did not (P ! 6E-11;
Figure 6B). Interestingly, 33 of the selected 62 CpG residues were
located in the PcG target-enriched DMC 2, which is 31 times more
than would be expected by chance (P ! 1.4E-97).
Figure 2. Unsupervised complete linkage hierarchical clustering of samples according to methylation of the 2764 differentially methylated CpG sites. There are
2 outliers and 6 major clusters of samples. The normal samples clustered together within cluster one (gray) and are marked by gray boxes below the dendrogram. Mutational
status is indicated below; white boxes represent wil -typ ; and colored boxes, mutations. P values are given for unequal distribution between clusters for each mutation using
the Fisher-Freeman-Halton test (outliers were disregarded). The frequency of NPM1 mutations is increased in cluster 2 and 6, IDH1 in cluster 6, and IDH2 in cluster 2.
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feasible that their influence on DNA methylation would differ. This is a novel finding 
that is quite interesting, not least since IDH1 and IDH2 mutations are almost mutually 
exclusive[131, 132]. 
 
4.5 GENOME WIDE METHYLATION PATTERNS MEASURED WITH 
ILLUMINA ARRAYS ASSOCIATE WITH CLINICAL OUTCOMES IN 
CN-AML 
 
In paper I a rough analysis of the average β-
values of the 20 samples that were subjected to 
Illumina array analysis proved to significantly 
correlate with overall and disease free survival. 
The finding was unexpected and serendipitous, 
but nevertheless significant (figure 11). 
 The patients selected for Illumina array 
investigation were all under 67 years of age, 
meaning that roughly the same patients that were 
divided by LUMA global methylation values 
were similarly divided in this analysis, given the 
correlation between the analyses (see section 4.2 
and figure 8). In paper II, in the test cohort of 58 
patients we could not repeat the prognostic 
implication of average β-values of the Illumina 
27k arrays. However, when refining the analysis 
and limiting it to the PcG target genes, we found 
that the average β-values of these was a strong 
and independent prognostic factor and, 
importantly, we could validate this in an 
independent cohort of 60 patients, figure 12. It 
may well be that in paper I, the average β-values 
of the whole Illumina 27k array, and also the 
LUMA values, were a proxy for the PcG target 
gene methylation status. One plausible 
 
Figure 11 Prognostic value of the number of CpG sites hypermethylated according to the Illumina 
Methylation array, divided at median, for (c) disease-free survival (n=15) and (d) overall survival 
(n=20). 
 
Table 5 The most significantly 
differentially methylated genes for 
achievement of complete remission (CR) 
and 2 year survival. * marks PcG target 
genes. 
 
p15, HIC1 and CDH methylation, as well as that of global DNA
methylation, in a large cohort of genetically and clinically well-
defined AML patients undergoing induction chemotherapy. The
analysis was performed to study the effect of methylation on
clinical outcome and response to therapy as well as its relation
to genetic subtypes of AML. We also performed an analysis of
genome-wide promoter-associated methylation using Illumina
HumanMethylation27 BeadChip array technology in a subset of
20 patients.
Important novel observations in this study are the associations
between global DNA methylation as well as p15 promoter
methylation and clinical outcome. Other novel findings were
the prognostic significance of the number of hypermethylated
CpG sites as measured by Illumina Infinium for DFS and OS as
well as the inverse association between global DNA methylation
and genome-wide promoter methylation.
Our data suggest the existence of a subset of AML cases with
good prognosis, characterized by low global DNA methylation
levels paired with increased p15 methylation as well as genome-
wide promoter-associated methylation levels, mainly discern-
able in younger patients.
Global DNA hypomethylation is a common phenomenon
in cancer4,23 and an indicator of good prognosis in acute
lymphoblastic leukemia,24 whereas it is a poor prognostic
marker in breast cancer.25 In AML, a decrease in global DNA
methylation at relapse compared with diagnosis was observed in
one study; however, these patients were selected on the grounds
of having relapsed, which makes comparisons with our study
difficult.26 Mechanistically, global DNA hypomethylation may
have a role in cancerogenesis through increased genomic
instability, activation of oncogenes or retrotransposons.27 The
reason for the increased CR rates in patients with global
hypomethylati n observed in our study is unclear. There were
somewhat fewer patients with adverse and more with favorable
karyotype in the hypomethylated group, but these differences
were not significant and were not retained in multivariate
analysis. Recent data show increased global LUMA methylation
in cell lines resistant to daunorubicin in comparison to their
sensitive counterparts (own unpublished data), suggestive of a
possible association with drug resistance. Further studies on this
matter are warranted, especially to determine whether demethyl-
ating agents could sensitize resistant cells to conventional
cytos atic drugs in AML, which has already been shown in vitro
in other cancers.28,29 Furthermore, our analysis showed that
global LUMA methylation data were prognostically important
mainly in patients younger than 65 years. One explanation for
this could be that intra-individual methylation variation accel-
erates with increasing age, which could affect both global and
gene-specific methylation and hence make cross-sectional
analyses such as ours less predictive in an older population.30,31
Differences in correlations with CR versus survival for prog-
nostic factors are not uncommon in AML. Although obviously
correlated, CR and survival represent s mewhat differe t effects
on the disease, which may explain the differences in outcome
on these variables. We also found an inverse relationship
between global methylation levels as measured by LUMA
and CpG island-related genome-wide methylation levels as
measured by Illumina HumanMethylation 27. LUMA analysis is
based on the HpaII/MspI recognition sequence, 50-CCGG-30,
which are fairly well intersperse through the genome. Approxi-
mately 50% of the CCGG sites are located in repetitive
DNA sequences and 50% in unique sequence,3 and even
though they are ccumulated at CpG islands, CpG islands only
comprise about 1% of the genome.31 Therefore, methylation
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Figure 4 Prognostic role of gene-specific and global promoter methylation in AML patients. Kaplan–Meier diagrams showing the prognostic effect
of p15 promoter methylation by DGGE on (a) disease-free survival (n¼104) and (b) overall survival (n¼ 78) as well as the number of CpG sites
hypermethylated according to the Illumina Methylation array for (c) disease-free survival (n¼ 15) and (d) overall survival (n¼ 20).
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explanation of the powerful prognostic impact could be the central role of Homeobox 
(Hox) gene methylation in AML pathogenesis. Hox genes encode DNA binding 
proteins central in embryonic development and hematopoiesis, and their expression is 
epigenetically regulated by PcG and Trithorax proteins[277]. They are highly enriched 
in our cohort among the differentially methylated genes. Hox genes are overexpressed 
in AML with mixed lineage leukemia translocations, which is a marker of poor 
prognosis[278]. Several authors have found that high expression of Hox genes 
correlates with poor prognosis and low expression with favorable prognosis, 
compatible with our results[279, 280]. Other possible explanations are offered when 
looking at the most significant genes associated with outcome (Table 5), many of 
which are PcG targets. Interestingly, several potassium channel encoding, PcG-
targeted, genes were on the list of methylated genes associated with 2-year survival. 
Potassium channels have been associated with AML prognosis, with low expression 
being a favorable prognostic factor[281, 282]. 
 
 
 
 
Figure 12 Kaplan-Meier diagram showing the impact of the methylation levels of PcG-marked 
genes on OS and PFS. The samples were divided in tertiles according to the average methylation 
levels of PcG-marked genes. The tertile with most methylation (tertile 3), marked with a solid line, 
had significantly better OS (C) and PFS (D) than the less methylated tertiles; in the test cohort (top 
panels): P(trend)=0.001 and 0.002, respectively. In the validation cohort (bottom panels): 
P(trend)=0.009 and P(trend)=0.035 (middle panels), and for pooled samples: P(trend)=0.00009 and 
0.0002, respectively. 
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Figure 13 Kaplan-Meier diagram showing the impact of 
the methylation levels of HOX genes on OS. The samples 
were divided in tertiles (38 in each) according to the 
average methylation levels of PcG-marked genes. The 
tertile with most methylation (tertile 3), marked with a 
dashed line, had significantly better OS.  
P(trend)=0.00003 
 
A further analysis of the implication of clustered 
(cluster A-D) Homeobox (HOX) gene average methylation levels revealed that they 
were an as strong predictor of overall survival as all PcG targeted genes (figure 13).  
 
4.6 ABERRANT METHYLATION OF THE BTG4 / miR 34-b/c PROMOTER 
IN CLL WITH FUNCTIONAL CONSEQUENCES 
In a previous study in CLL, SNP-chip technique demonstrated a large commonly 
deleted region at 11q, similar to what has been reported previously[283]. However, one 
case with 11q-deletions showed two small deleted regions with a small heterozygote 
region in between. One of the deleted regions contained the ATM gene whereas the 
other contained 6 other genes (POU2AF1, BTG4, FLJ46266, LAYN, SNFLK2 and 
PPP2R1) as well as microRNA-34b/c (miR-34b/c). BTG4 and miR-34b/c are directed 
from a shared two-way promoter that has been characterized in detail by Toyota et al in 
colon cancer[284]. In CLL with deletion of the 11q region, the ATM gene is implicated 
as a tumor suppressor, but is only mutated in 30% of CLL cases. There is 
circumstantial evidence that there is another tumor suppressor gene in the region and 
several have been suggested[226, 285, 286]. We searched the genes of the 
microdeletion for epigenetic silencing and found a high degree of aberrant methylation 
in the BTG4 – miR34b/c promoter, 25/52 (48%) with MS-MCA. None of the other 
genes has similar degrees of aberrant methylation (table 6). To validate the MS-MCA 
findings, primers for bisulfite pyrosequencing were constructed and 29 of the 
investigated samples including two healthy controls were sequenced. The primer 
locations are shown graphically in relation to BTG4 and miR-34b/c in figure 14. 
Results were highly concurrent with the MS-MCA results (p=0.001, Mann-Whitney). 
 
 
 
 
Figure 14 CpG sites (vertical bars) and 
primers in relation to the BTG4 and miR-
34b/c gene and promoter regions. 
 
 
 
 Interestingly, there was no significant correlation with 11q deletions; 19/35 (54%) 
were methylated of non-11q deleted compared to 5/16 (31%) of 11q deleted CLL cases 
(p=0.126). There was a trend towards increased methylation in IgVH mutated samples, 
63% vs. 39% (p=0.099). No correlations between del17p, trisomy 12, del13q or the 
oligonucleotide containing the p53RE2 sequence upstream of the
pGL3-miR-34b/c reporter (Supplementary Fig. S2). Cotransfection
of the reporter with a p53 expression vector markedly up-regulated
luciferase expression, confirming that transcription driven from the
miR-34b/c CpG island can be stimulated by p53 (Supplementary
Fig. S2).
Analysis of DNA methylation in the miR-34b/c CpG island.
To test whether DNA methylation in the miR-34b/c CpG island is
responsible for silencing, we first carried out MSP analysis and
found that the CpG island is significantly methylated in all of the
CRC cell lines tested (Fig. 3C). By contrast, DKO2 cells and normal
colonic mucosa showed strong signals, indicating the absence of
methylation (Fig. 3C). We then verified the MSP results by carrying
out bisulfite sequencing in selected samples. This sequencing
analysis revealed that the CpG sites in this region were extensively
methylated in the three CRC cell lines tested, whereas almost no
methylation was seen in DKO2 cells (Fig. 3D).
We also carried out a quantitative analysis of the methylation
of seven CpG sites in the core region of the CpG island using
primers designed for bisulfite pyrosequencing (Fig. 3A and
Supplementary Fig. S3A). The average methylation levels in
HCT116, RKO, and DLD-1 cells were 85%, 90%, and 67%,
respectively, but it was only 4% in DKO2 cells (Supplementary
Fig. S3B), which is highly consistent with the bisulfite sequencing
analysis (Fig. 3D).
Methylation and expression analysis of miR-34b/c in
primary CRC. We next analyzed the methylation of the miR-
34b/c CpG island in a panel of tumor specimens from CRC
patients. MSP analysis revealed that the miR-34b/c was methyl-
ated in 101 of 111 (90%) primary CRCs tested. By contrast, little
or no methylation was detected in samples of normal colonic
mucosa from the patients, indicating that methylation of the miR-
34b/c region is a tumor-specific phenomenon (Fig. 4A). We
confirmed these results by bisulfite sequencing in selected
specimens. In samples of normal colonic tissue, a small number
of alleles showed some spotty methylation, but the majority of
alleles were completely unmethylated (Fig. 4B and Supplementary
Fig. 4). On the other hand, the tumor tissue showed a mixture of
entirely or partially methylated alleles and unmethylated alleles,
probably reflecting contamination of the sample by normal cells
Figure 3. Promoter activity and methylation analysis of the miR-34b/c CpG island in CRC cells. A, diagram of the 5¶ CpG island of miR-34b/c . Solid box indicates exon
1 of BTG4 , and an arrow indicates miR-34b . The regions analyzed by MSP, bisulfite sequencing, and bisulfite pyrosequencing are indicated by bars below the
CpG sites. The predicted promoter regions are indicated by gray arrows. Areas containing the predicted promoter regions were cloned into pGL3-basic. B, promoter
reporter assay results in indicated CRC cell lines. Normalized luciferase activities are represented. Columns, means of four replications; error bars, SDs. C, MSP
analysis of the miR-34b/c CpG island in a set of CRC cell lines and a sample of normal colonic tissue. In vitro methylated DNA (IVD) and DKO2 serve as positive
and negative controls, respectively. Bands in the ‘‘M’’ lanes are PCR products obtained with methylation-specific primers; those in the ‘‘U’’ lanes are products
obtained with unmethylated-specific primers. D, bisulfite sequencing of the miR-34b/c CpG island in the indicated CRC cell lines. Open and filled circles represent
unmethylated and methylated CpG sites, respectively.
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/ negative cases evaluated with MS-
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combination of 11q and 17p deletions and BTG4/miR-34b/c methylation were found. 
Importantly, when we stress incubated primary CLL cells with Doxorubicin, we found 
that miR-34b/c, but not BTG4, was up-regulated in samples that were unmethylated 
compared to methylated samples, P=0.038 (figure 15, upper panel). This effect was not 
found, perhaps attenuated, when the TP53 activating agent PRIMA1 or the 
demethylating agent Decitabine was used for incubation, P=0.6 (figure 15, middle and 
lower panel). Furthermore, cases with miR-34b/c methylation had a better overall 
survival than non-methylated cases (figure 16). The significance of methylation 
however disappeared when a multivariable Cox regression model including IgVH-
status, age and 11q status was applied. The miR-34b/c analogue miR-34a is located on 
chromosome 1p and has been implicated as a tumor suppressor in CLL[287], making 
the discovery of methylation of the miR-34b/c promoter highly interesting. miR-34a 
and the clustered miR-34b/c are transcriptional targets of p53 and reintroduction of 
miR-34s in deficient cells increases apoptosis and decreases growth[288]. Furthermore, 
miR- 
34b/c are silenced by hypermethylation in oral squamous cell carcinoma, gastric 
cancer, malignant melanoma and colon cancer[284, 289-291] and are considered tumor 
suppressors in these cancers[292]. The shared promoter of BTG4 and miR-34b/c makes 
it difficult to determine which of these genes have tumor suppressive functions only by 
methylation analysis. We therefore conducted functional experiments, showing that a 
TP53-activating drug, doxorubicin, selectively induced miR-34b/c transcripts but not 
BTG4, implying a functional role in drug resistance or apoptotic mechanisms, 
previously shown for miR-34a[287]. Somewhat surprising, we did not find any 
associations between miR-34b/c methylation and 11q or 17p deletions. This may be 
due to low power as only 6 samples with 17p deletion were included in the study. Still, 
a trend could be seen towards more methylation in IgVH mutated samples (p=0.099). 
The finding is somewhat provoking since ATM mutations and also p53 mutations 
occur almost exclusively in IgVH unmutated CLL, leaving the door open for other 
oncogenic mechanisms in IgVH mutated cases, where miR34b/c methylation is more  
common. This would also be compatible with our observation of better survival in 
BTG4/miR-34b/c mutated patients, a prognostic factor that became non-significant  
when corrected for age, deletion 11q and IgVH status. 
 
 
 
 
Figure 15 Panels show miR-
34b/c expression measured as 
the expression ratio (normalized 
to RNU6) of drug vs. mock 
incubated samples. Panels on the 
left show miR-34b/c levels in 
relation to methylation status. 
 
 
 
Figure 16 Kaplan-Meier curve of 
overall survival of 47 patients with 
methylated (green) of unmethylated 
(blue) BTG4/miR-34b/c promoter. 
Methylation at the BTG4-miR34b/c 
locus was associated with significantly 
improved overall survival (P=0.024, 
Log-Rank) 
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5 CONCLUSIONS 
 
Paper I: Our results show that low global DNA methylation levels measured with 
LUMA correlate with an improved CR rate and that methylation of p15, measured with 
DGGE, may be an independent prognostic factor in AML. We also show an inverse 
correlation between global DNA methylation and genome-wide promoter methylation 
and an association between the number of hypermethylated CpG sites measured 
genome-wide by the Illumina HumanMethylation27 array and prognosis.  
 
Paper II: In conclusion, we show that NPM1 and IDH mutations associate with specific 
clusters of samples, that PcG target genes have an increase of aberrant methylation 
compared with other genes, and that the level of PcG target methylation may be an 
independent prognostic factor for clinical outcome in CN-AML. We suggest that 
methylation patterns may be used as new tools to predict outcome in AML patients and 
that there are potentially new subgroups of AML that could be defined by methylation 
patterns. 
 
Paper III: We show for the first time that miR-34b/c promoter, located at the commonly 
deleted region of chromosome 11q, is aberrantly hypermethylated in nearly half of CLL 
cases, regardless of karyotype, but with a trend of less methylation in IgVH unmutated 
cases. We also show that silenced miR-34b/c expression can be induced by stress 
signals such as a through exposure to a cytotoxic drug, an effect that seem to be 
dependent on methylation status. However, further studies on the importance of miR-
34b/c methylation in CLL are needed. 
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6 FUTURE PERSPECTIVES 
6.1 IS THERE AN EPIGENETICALLY DRIVEN SUBSET OF AML? A 
HYPOTHESIS 
Our paper I and paper II show that epigenetic changes in AML have prognostic 
implications, and in paper II the most important epigenetic changes for prognosis can 
be narrowed to the Polycomb group targeted genes. Further analysis, presented in this 
thesis (figure 13), implies that the clustered Homeobox (HOX) genes are the core set of 
these prognostic PcG target genes. These are genes that are important in embryogenesis 
but also pivotal for hematopoetic and myeloid differentiation. They are expressed in an 
orderly and strictly regulated fashion, meaning that epigenetic impairment of one may 
lead to silencing or disorderly repression of other HOX genes and non coding-RNAs 
“caudally” in the same cluster, even if these genes in themselves were not functionally 
incapacitated. Given the results of our research with better survival of CN-AML cases 
with HOX gene methylation, we can formulate a testable hypothesis; that epigenetic 
impairment of HOX genes is a common mechanism effectuating differentiation block in 
AML.  
Larger studies of DNA methylation of HOX and PcG targeted genes in AML samples 
well characterized cytogenetically and molecularly could further define the context of 
this epigenetic mechanism and, importantly, define its prognostic role in relation to 
allogeneic stem cell transplantation, opening the possibility for clinical utilisation in 
therapeutic decision making. Further functional studies and the development of a cell 
line system that could be utilized for drug screening, would open up for translation of 
this new knowledge into clinically useful applications. 
 
6.2 ESTABLISHING THE ROLE OF MICRO-RNA-34B/C IN CLL 
Our paper III deals with the role of miR-34b/c as a plausible tumor suppressor gene on 
chromosome 11q in CLL. To conclude whether this is a true tumor suppressor further 
functional experiments should be undertaken, both knock out experiments and rescue 
knock in, preferably using transfection of anti-sense RNA and micro-RNAs in a cell 
line model, observing the impact on proliferation and apoptotic ability. If proven to be a 
tumor suppressor gene, the possibilities of utilising synthetic oligomers, for instance 
locked nucleic acids (LNA:s), as therapeutic agents is a fascinating road ahead. 
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